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Disseminated intravascular coagulation (DIC) is not an independent disease entity but rather an in termediary mechanism of disease and is usually seen in association with well-defined clinical entities. 1, 2 The pathophysiology of DIC serves as an intermedi ary mechanism of disease in many localized disease processes which, in some instances, remain organ spe cific. This catastrophic syndrome spans all areas of medicine and presents a wide clinical spectrum that remains confusing to many clinicians. The syndrome of DIC was referred to in the early literature as "con sumptive coagulopathy"; 3, 4 this is not an appropriate term because very little is consumed in DIC; most factors and plasma constituents are plasmin biodegraded. Terminology that followed this initial descrip tive phrase was that of "defibrination syndrome"; 5, ' 6 however, a more appropriate term would be a "defibrinogenation syndrome." The most common and current terminology "DIC" is a good descriptive patho physiologic term if one accepts that coagulation rep resents hemorrhage plus thrombosis. 7 Most consider DIC to be a systemic hemorrhagic syndrome; however, this is only because hemorrhage is obvious and often is impressive. What is less com monly appreciated is the significant amount of micro vascular thrombosis and, in some instances, large ves sel thrombosis that is also occurring. In fact, the hemorrhage is often easy to contend with in patients with fulminant DIC, and it is the small vessel and large vessel thrombosis with impairment of blood flow, ischemia, and associated end-organ damage that usually leads to irreversible morbidity and mortality of the patient. Thus, DIC is a syndrome associated with hemorrhage, which is often clinically obvious, and with diffuse thromboses, which may lead to irre versible end-organ damage and death; it is this latter complication that is difficult to stop or reverse.
Throughout this text, acute versus chronic DIC and the attendant differences in clinical manifesta tions, laboratory findings, and treatment will be dis cussed. However, it should be realized that these are often pure and often theoretical clinical spectrums of a disease continuum, and patients may present any where in this continuum and, in fact, may lapse from one end of the spectrum to the other.
HISTORICAL PERSPECTIVES
The first description of DIC comes from a lec ture delivered by Walter H. Seegers, then Professor and Chairman of the Department of Physiology at Wayne State University, to the Cincinnati Academy of Medicine on April 18, 1950 , and subsequently pub lished in that Academy's journal. 8 This lecture gave special reference to Factor V, which had recently been discovered. During this presentation, it was postulated that "thromboplastin" may gain access to the mater nal circulation and cause hemorrhagic problems. Several essential steps in developing this concept were discussed and thus served as the first logical patho logic thinking regarding DIC. Seegers recognized that thromboplastin was present in many tissues and could initiate the blood clotting mechanism directly by activating prothrombin. In addition, when thrombo plastin was deliberately placed in the circulation of animals, a variety of pathologic responses were ob tained. Seegers also recognized that in experimental animal models mechanical trauma of the placenta released material that was likely to be thromboplastin and induced a variety of pathologic changes in the animal. Also, a study of human cases revealed that many of the pathologic lesions corresponded to those produced by thromboplastin in animal models. Shortly before delivering this lecture, Seegers and his col league Charles L. Schneider had been able to demon strate that amniotic fluid and placenta contained a large amount of thromboplastin. Seegers also noted that, during observations in animal models, the injec tion of thromboplastin caused cessation of blood flow in small vessels altogether, and, if the animals were carefully examined, it was found that death was due to characteristic intravascular thrombotic lesions and that thromboembolism was present throughout the pulmonary vascular tree. It was also found that the central nervous system was damaged by perivascular hemorrhage and, additionally, liver necrosis was pres ent. Thus, Seegers not only first described DIC and offered a pathophysiologic mechanism, but also re cognized that hemorrhage plus thrombosis is the usual clinical result. These observations were extended to several patients who were discussed in this early lec ture; three of these patients were instances of eclamp sia. In addition, Seegers described a case of complete placental abruption with nearly complete "defibrin ation" in the patient; this was demonstrated by repeated laboratory assays for circulating fibrinogen.
These studies were expanded on and reported at the IVth American Congress on Obstetrics and Gyne cology in 1951. 9 During this presentation the inves tigators focused attention on thromboplastin and reviewed reasons why thromboplastin might be re sponsible for a group of "perplexing disorders" of late pregnancy, including the intracranial hemorrhagic di athesis of pregnancy, and toxemia of pregnancy. These investigators also recognized that thromboplastin led to an underlying disease process of intravascular co agulation, with thromboplastin presumably entering the bloodstream, and although this material initiates the blood clotting mechanism or procoagulant system, it may be carried some distance and mixed with a variable volume of blood before fibrin starts to form in the microcirculation. This process of coagulation then results in a depletion of fibrinogen and a resul tant extensive defibrination, and following this blood was noted to be refractory to further injections of thromboplastin because of inadequate fibrinogen. They stated "by the same token, however, animals are subject to grave danger due to uncontrolled hemor rhage, for an important portion of the hemostatic mechanism has been depleted." They concluded by pointing out that the mechanism of thromboplastin in troduction to the systemic maternal circulation needed to be considered a factor in several complications of late pregnancy and not simply as one type of compli cation because the resultant foci of tissue destruc tion in different organs will cause differing clinical manifestations.
Also at this same meeting Seegers and Schneider 9 documented and quantitated the degree of thrombo plastin or procoagulant material that could be obtained from the placenta, decidua, and amniotic fluid. In addition, they presented a hypothetical mech anism by which intravascular coagulation might occur due to this thromboplastin material. It was proposed that maternal blood within a retroplacental hematoma became admixed with material fragmented from or leached out of the torn uterine decidua within which the hematoma was enclosed. This mixture, rich in thromboplastin material from the decidua, could then enter the circulation by one path or another, with the most likely path being into the maternal lake within the placenta. Once within the maternal lake, this ad mixture would be likely to be distributed throughout the maternal circulation. Thus, these are the first descriptions of clinical DIC.
In the same year in the Harvey Lectures Seegers 10 further reported on decreases in Factor V as well as fi brinogen during the hemorrhagic complications of pregnancy. In 1952 this important work was further expanded and reported. 11 In this report was de scribed and incorporated the role of the accelerated conversion of prothrombin to thrombin, thus leading to subsequent defibrinogenation and hemorrhagic complications of pregnancy. 11 In 1953, this original work was extended to the clinical field and published by Seegers and coworkers, 12 who developed guide lines for early cesarean section to abort the hemor rhagic syndrome, which they called "defibrination." Major clinical extensions of this initial observation were shortly thereafter reported by Ratnoff and co workers. 13, 14 In this two part article, many profound observations were described, including the following: the hemorrhagic syndromes of pregnancy included premature separation of the placenta, amniotic fluid embolism, the presence of a dead fetus in utero, and severe preeclampsia or frank toxemia of pregnancy. In addition, they recognized that a generalized bleed ing tendency may occur as a sequel to "criminal abor tion." It was also noted that the treatment of a patient with a hemorrhagic diathesis associated with prema ture separation of the placenta consisted, most impor tantly, of early evacuation of the uterus; it was pointed out that if labor did not occur promptly, it was diffi cult to keep a patient out of shock, or if laboratory tests revealed progressive hypofibrinogenemia, it was probably in the best interest of the patient to empty the uterus promptly by cesarean section. The reader will appreciate that this was profound thinking for 1955 . In addition, in the conclusion of this article it was recognized that more than simply hypofibrinogenemia was accounting for the hemorrhagic syn dromes associated with pregnancy, and it was also noted that an "unexplained prolongation of the clot ting time and associated severe thrombocytopenia" were present. Thus, it was again recognized that mul tiple hemostatic defects were present. In addition, Ratnoff and coworkers 13 ' 14 were the first to note that in patients with amniotic fluid embolism, hemorrhagic symptoms appeared even though the concentration of fibrinogen in the plasma did not seem to be suffi ciently low to account adequately for ineffective hemostasis. This, then, was the first description of a multifaceted defect that accounted for the hemor rhage of DIC.
Additional observations were that: "fibrinolysin was thought to be present," thus also rendering the first description of secondary activation of the fibri nolytic system and probably the most important cause of hemorrhage in these patients. In these articles by Ratnoff and coworkers 13, 14 is to be found the first report of septicemia associated with DIC. Two pa tients were described who had undergone attempts at self-induced abortion and subsequently developed bacteremia with gram-negative coliform bacilli.
In 1962, Ratnoff and Nebehay 15 published an article on the severe alterations in blood coagulation that may sometimes contribute to the bleeding ten dency and shock in the Waterhouse-Friderichsen syn drome. Also reported was a case of DIC associated with incoagulable blood with prolonged clotting and bleeding times, thrombocytopenia, and low levels of fibrinogen, Factor V, and Factor VII in a patient with the Waterhouse-Friderichsen syndrome induced by infection with pneumococcus. Following this, addi tional reports of DIC began to appear in the literature and finally in the mid-1960s, DIC became a clinically accepted and readily recognized syndrome. However, we owe our basic understanding and appreciation of this syndrome to the astute clinical and laboratory observations of Seegers and Ratnoff and their co workers; the reader is encouraged to peruse these early descriptions of DIC for a complete appreciation of the discoveries that may be made by careful bio chemical observation and equally astute clinical obser vation.
ETIOLOGY

Acute DIC
DIC is usually seen in association with welldefined clinical entities and those clinical entities that are most commonly associated with acute DIC are summarized in Table 1 .
Obstetric accidents are common events leading to DIC. Amniotic fluid embolism and associated DIC are the most catastrophic and common of the lifethreatening obstetrical accidents. 16, 17 The syndrome of amniotic fluid embolism is manifested by the acute onset of respiratory failure, circulatory collapse, shock, and a most serious thrombohemorrhagic syndrome of DIC. The first careful description of this syndrome was by Steiner and Lushbaugh in 1941. 18 In this land mark description, these investigators describe the clin ical histories of eight obstetric patients and demon strated that these patients formed a distinct group with a unique pathophysiologic basis for the constel lation of symptoms now associated with this syn drome. These eight patients came from 4000 consecu tive autopsies performed over a period of 15 years, representing an incidence of 0.2% of deaths in their autopsy series. Also in this study, it was recognized that these eight patients were among a total of 24,200 deliveries, thus representing an incidence of 1 in 8000 of their obstetric cases. These investigators, when ana- lyzing their data, were the first to show that amniotic fluid embolism was the most common cause of mater nal death in the period between labor and the first 9 hours postpartum. The common etiologic factor in this syndrome of amniotic fluid embolism is the en trance, by various proposed mechanisms and routes, of amniotic fluid into the systemic maternal circula tion followed by embolization of amniotic fluid and its contents to the lungs; subsequently, circulatory col lapse and the development of DIC occurs almost uni formly. The incidence of this catastrophic syndrome has been reported to be between 1 and 8000 and 1 and 30,000 births. 18, 19 The syndrome is commonly fatal for both mother and child. Although the finding of amniotic fluid in maternal blood is not physiologic, there are rare instances when amniotic fluid may enter the systemic maternal circulation without significant manifestations of this catastrophic syndrome. 20 In a 1970 study it was noted that the syndrome of amni otic fluid embolism represented 10% of all maternal deaths, and a study in Sweden from 1965 to 1974 demonstrated that the syndrome of amniotic fluid em bolism accounted for 22% of all maternal deaths. 21, 22 The risk factors associated with the development of amniotic fluid embolism are depicted in Table 2 , in cluding marked exaggeration of uterine contraction following rupture of the uterine membranes or due to the use of oxytocin or other uterine stimulatory agents. 18, 23, 24 The syndrome can, on rare occasions, occur late in pregnancy, but most commonly occurs during labor in 80% of patients; in only up to 20% of pa tients does the syndrome occur before labor begins and before rupture of the amniotic sac. 25, 26 Twentyfive percent of women will die within 1 hour of devel oping this syndrome and up to 80% of patients will die within the first 9 hours. 27, 28 It is of interest to note that in 10% of women the syndrome develops without premonitory warning, usually during delivery, as amniotic fluid enters the systemic maternal circu lation during an apparently normal labor.
There is generally rapid onset of signs and symp toms of pulmonary failure and circulatory collapse; in at least 50% of women this is followed by systemic bleeding. Fifty percent of fetuses die or develop intra uterine distress before the sudden maternal onset of acute respiratory failure and circulatory collapse. The cause of amniotic fluid embolism is only partially un derstood, but the common causative event is entrance into the systemic maternal circulation of amniotic fluid, which then causes extensive pulmonary microcirculatory occlusion and local pulmonary activation of the procoagulant system; in addition, there is sys temic activation of the procoagulant system. This occurs in conjunction with intense induction of pul monary fibrinolytic activity, presumably via release of pulmonary endothelial plasminogen activator activity in the lungs. Since this is a life-threatening and com mon syndrome, all clinicians involved with obstetrics and delivery should be familiar with the risk factors depicted in Table 2 and with the patient, immediately preceding, during, or immediately after delivery, who suddenly develops respiratory distress, shock, and uncontrolled bleeding. The general characteristics of amniotic fluid embolism are presented in Table 3 . Amniotic fluid contains significant cellular material, including vernix caseosa, squamous epithelial cells, and other debris from the fetus. 18, 29 The lipid con tent, cellular content, fetal debris, procoagulant activ ity, and viscosity of amniotic fluid all increase with duration of pregnancy and are at a maximum at time of delivery. 30, 31 In most incidences the actual mecha nism (or mechanisms) and site of entry of amniotic fluid into the uterine and, subsequently, systemic maternal circulation remain unclear.
The diagnosis of amniotic fluid embolism should be strongly suspected when there is sudden develop ment of acute respiratory failure during an otherwise normal delivery. The acute respiratory failure occurs from occlusion of pulmonary vessels by amniotic fluid, and intense vasoconstriction of pulmonary ves- sels and then further occlusion by platelet-fibrin thrombi. This initial event is usually followed by car diogenic shock and systemic cardiovascular collapse. The usual clinical findings of acute pulmonary insuffi ciency are the sudden onset of tachypnea, dyspnea, and peripheral cyanosis due to the abrupt develop ment of abnormal perfusion and diffusion. These findings are usually accompanied by acute cor pulmo nale with resultant right-sided failure with subsequent decreased filling of the left ventricle and resultant low output failure and peripheral end organ hypoxia, isch emia, and metabolic acidosis. Abnormal diffusion capacity, metabolic acidosis, and elevated central ve nous pressure are also noted. Figure 1 demonstrates a fetal squamous cell in a maternal pulmonary capil lary.
The approach to management of acute respira tory failure in these patients is straightforward and consists of immediate establishment of an airway, use of oxygen, and a mechanical ventilator if needed. Cir culatory collapse must be managed immediately with the use of vasoconstrictive agents, usually dopamine. Other cardiovascular and respiratory modalities may also be needed. Circulatory collapse is further man aged by volume replacement. Management of DIC, as will be discussed subsequently, should be via immedi ate use of heparin to stop quickly further deposition of platelet-fibrin thrombi and further generation of activated coagulation factors.
In instances of placental abruption, placental enzymes or tissues, including thromboplastin-like ma terial, may be released into the uterine and subse quently the systemic maternal circulation and likewise lead to activation of the coagulation system.
In the retained fetus syndrome the incidence of DIC approaches 50% if the woman retains a dead fetus in utero for greater than 5 weeks. The first find ings are usually those of a chronic compensated DIC, which then amplify into a more fulminant hemor rhagic-thrombotic DIC. In this instance necrotic fetal tissue as well as enzymes derived from necrotic fetal tissue are released into the uterine and then the sys temic maternal circulation and at various points acti vate the procoagulant system and trigger an episode of acute DIC. 32, 33 Intravascular hemolysis of any cause is a com mon triggering event for DIC. A frank hemolytic transfusion reaction is certainly a triggering event for DIC; however, hemolysis of any cause, even minimal, may provide a trigger. During hemolysis, the release of red cell adenosine diphosphate (ADP) or red cell membrane phospholipoproteins may activate the procoagulant system and in clinical practice a combina tion of these may account for episodes of DIC asso ciated with major or minor hemolysis. [34] [35] [36] [37] [38] An example of this is the use of multiple transfusions with banked whole blood over a short period of time. For example, the use of 5 to 10 U of banked whole blood within a 24-hour period will provide a significant trigger for DIC via the aforementioned mechanisms. Thus, he molysis due to a frank hemolytic transfusion reaction or even to a minor hemolytic reaction with release of red cell ADP or red cell membrane phospholipopro teins is capable of providing a trigger for activation of the procoagulant system and a subsequent episode of acute DIC.
Septicemia is often associated with DIC. An early organism to be associated with DIC was the menin gococcus. [39] [40] [41] Later, other gram-negative organisms were also noted to provide a triggering event for DIC. 42, 43 The triggering mechanisms have been well described and consist of the initiation of coagulation by endotoxin: bacterial coat lipopolysaccharides. 44, 45 Endotoxin has the ability to activate Factor XII to Factor Xlla, to induce a platelet release reaction, to cause endothelial sloughing with subsequent activation of Factor XII to XIIa or Factor XI to XIa, or to initi ate a release of granulocyte procoagulant materials; any one of these might independently trigger DIC. However, what is most likely commonly seen is a clin ical summation of several or all of these activation sequences. Following these observations, numerous gram-positive organisms were also noted to be asso ciated with DIC and, likewise, the mechanisms have been aptly described. 46, 67 Bacterial coat mucopolysac charides may demonstrate exactly the same activity as endotoxin, namely, the activation of Factor XII to Factor XIIa, a platelet release reaction, endothelial sloughing, or the release of granulocyte procoagulant materials, any one of which may initiate DIC. How-
FIG. 1. A fetal squamous cell shown in a capillary of the mother.
This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. ever, as with gram-negative endotoxemia, what is most likely seen is a clinical summation of several or all of these activation events. Numerous viremias have been reported to be associated with DIC and the most common are vari cella, hepatitis, or cytomegalovirus infections. 48, 49 However, many other acute viremias may also induce DIC. 2 The exact triggering mechanisms are poorly documented; however, the most likely mechanism is that of antigen-antibody associated activation of Fac tor XII, a platelet release reaction, or endothelial sloughing with subsequent exposure of subendothelial collagen and basement membrane. [50] [51] [52] Severe viral hepatitis and hepatic failure can lead to DIC. In addi tion, intrahepatic or extrahepatic cholestasis may be accompanied by acute DIC.
Cancer is often associated with DIC and most persons with disseminated solid malignancy will have at least laboratory evidence of DIC, which may or may not become clinically manifested. If one there fore looks for laboratory evidence of DIC in patients with disseminated solid malignancy, it is almost always found. [53] [54] [55] [56] There are many mechanisms by which malignancy may provide a trigger for initiation of DIC. One such mechanism is simply neovasculariza tion of tumor; the "new vasculature" is comprised of abnormal endothelial lining, which may activate the procoagulant system by several mechanisms. 57, 58 In addition, solid tumors may release necrotic tumor tis sue or tumor cell enzymes into the systemic circulation and activate the coagulation sequence. 59, 60 Other mechanisms may also be operative in malignancy; for example, the sialic acid moiety of mucin in mucinous adenocarcinoma tissue is capable of the nonenzymatic activation of Factor X to Factor Xa, which may then lead to an acute or chronic compensated DIC and this may be manifested in the usual manner or as multiple or single thrombosis. 61, 62 It has long been debated whether prostatic carci noma is associated with a primary hyperfibrino(geno)lytic syndrome or DIC. Rapaport and Chapman 63 have clearly shown that malignant prostatic tissue secretes enzyme-type materials that are capable of activating the coagulation system and are associated with the usual secondary fibrinolytic response, which represents a typical DIC syndrome. 64, 65 In addition, these investigations have demonstrated that malignant prostatic tissue may secrete materials that indepen dently activate the fibrinolytic system, converting plasminogen to plasmin. Thus, patients with prostatic carcinoma develop a typical DIC syndrome with sec ondary fibrinolysis and, in addition, develop primary activation of the fibrinolytic system. Thus, an over whelming fibrinolytic response is seen in these pa tients. This accounts for the clinical observation that these patients far more commonly present with hem orrhage rather than thrombosis. Studies done at the Mayo Clinic have revealed that there is a direct corre lation between laboratory findings of DIC before transurethral prostatectomy and degree of postprostatectomy blood loss, suggesting that it is prudent to look for evidence of DIC, as defined by elevated fi brin(ogen) degradation products (FDP) and circulating soluble fibrin monomers, because these findings may predict those patients who will bleed following surgery and may predict the need for postoperative blood replacement. 66 Pancreatic carcinoma has been classically associ ated with "migratory thrombophlebitis" and the mech anisms have been carefully studied and described. 67, 68 In this instance, the "migratory thrombophlebitis" is nothing more than a clinical manifestation of DIC. The incidence of thrombophlebitis in carcinoma of the pancreas is much higher in patients with carci noma of the body or tail as opposed to those with car cinoma of the head of the pancreas. When a carci noma is present in the body or tail of the pancreas, there is minimal ductal obstruction and thus large amounts of trypsin are released into the systemic cir culation. Trypsin, a serine protease, possesses activity much like thrombin or Factor Xa and thus may acti vate the coagulation system, and a typical DIC-type syndrome results. The clinical manifestation is more commonly thrombosis rather than hemorrhage, in contrast to that seen in prostatic carcinoma. Alterna tively, if the carcinoma is located in the head of the pancreas, ductal obstruction is pronounced and only minimal trypsin release occurs and disseminated throm boses are much less commonly seen.
In summary, many patients with disseminated solid malignancy demonstrate laboratory evidence of DIC. However, many patients never develop overt clinical manifestations of acute DIC even though a significant number may have laboratory manifesta tions of a chronic compensated DIC if it is suspected and subsequently looked for and documented.
Patients with leukemias of either acute or chronic types are also candidates for DIC. The most common acute leukemia that is associated with DIC is acute hypergranular promyelocytic leukemia. The mecha nisms for this have been carefully investigated and described by Gralnick and Tan 69, 70 as well as others [71] [72] [73] and consist of the release of procoagulant material from granules of the progranulocytes. Furthermore, Gralnick et al 74 and Bennett 75 have demonstrated that the use of heparin or miniheparin before the initi ation of cytotoxic chemotherapy may ward off the development of DIC and may significantly prolong This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
survival. It has certainly been my experience that if a patient with acute promyelocytic leukemia does not actually present with findings of DIC, the patient will almost always develop acute DIC when cytotoxic che motherapy is initiated; this is initiated by a large pop ulation cell "kill" and resultant release of granule procoagulant material into the systemic circulation and subsequent DIC. 2, 76 The next most common leukemia to be associ ated with acute DIC is acute myelomonocytic leuke mia. 77 However, any acute leukemia or, less com monly, chronic leukemia, may be associated with DIC and may significantly alter the prognosis of pa tients. 2, 71, 72, 76, 77 Any of the chronic leukemias can be associated with DIC, although much less commonly than the acute leukemias. 76 Malignancies commonly associated with DIC are listed in Table 4 .
Acidosis, and less commonly alkalosis, may also provide triggers for DIC. 2, [78] [79] [80] In acidosis the trigger ing event is most likely due to endothelial sloughing with the attendant activation of Factor XII to XIIa and/or Factor XI to XIa and platelet release with a subsequent activation of the procoagulant system. However, the mechanisms that are potentially opera tive in cases of alkalosis remain unclear.
Patients with extensive burns are common candi dates for DIC and several mechanisms may be oper ative. 81, 82 Microhemolysis with the attendant release of red cell membrane phospholipids and red cell ADP may provide the trigger. In addition, necrotic burn tis sue may be associated with the release of tissue mate rials and cellular enzymes into the systemic circulation to initiate a DIC-type process. Any patient with a large crush injury and attendant tissue necrosis may also develop DIC by the release of tissue enzymes or phospholipoprotein-like materials into the systemic circulation. 2, 76, 79 Selected vascular disorders and other miscella neous types of disorders may also be associated with acute DIC; however, these are more commonly asso ciated with a chronic form of this syndrome. 2, 83, 84 In particular, all are familiar with the Kasabach-Merritt syndrome, the association of giant cavernous heman giomas and DIC. 85, 86 Up to 25% of patients with giant cavernous hemangiomas will develop a chronic low-grade "compensated" DIC that may or may not progress into an acute DIC. The progression into an acute from a chronic compensated DIC may occur with or without any particular identifiable reason. Approximately 50% of patients with hereditary hem orrhagic telangiectasia will also have a chronic DIC syndrome and many of these patients may develop an acute DIC process for unexplained reasons. 87, 88 Patients with small vessel disease, such as vasospastic phenomena, including Raynaud's disease or severe diabetic angiopathy, or angiopathy associated with autoimmune disorders, may also develop chronic DIC, which may or may not become acute. 89 Vascular dis orders associated with DIC are given in Table 5 . Many chronic inflammatory disorders, including sarcoidosis, Crohn's disease, and ulcerative colitis, may also be associated with compensated DIC.
Selected prosthetic devices may also provide a triggering event for DIC. Exposure of the blood to foreign surfaces is often linked with activation of the procoagulant system and this may provide a major obstacle in the use of certain prosthetic devices. The use of prosthetic devices has become extremely com monplace in the management of patients with vascular disease, cardiac disease, renal disease, angiographic studies, and ascites. The hemostatic complications that accompany the insertion of prosthetic devices include activation of coagulation factors, "consump tion" of coagulation factors as well as other plasma proteins and platelets, and the generation of microthrombi, which may or may not be of clinical conse quence. In addition, thrombosis or thromboembolism may also give rise to serious life-threatening problems with prosthetic devices. 90 Intra-aortic balloon assist is a widely utilized clinical maneuver to control postmyocardial infarction cardiogenic shock, and to stabi lize selected patients after bypass surgery. Activation of the coagulation system with an attendant low-grade DIC, which may become fulminant and acute, may accompany the use of these devices. 90 LeVeen valve shunting for peritoneovenous shunting has become a common palliative procedure for the treatment of in tractable ascites associated with severe liver disease or malignant ascites. A generalized DIC-type syndrome is frequently seen with the use of the LeVeen shunt. 90 It has been noted that the removal of ascitic fluid at the time of valve implantation, as well as the use of selected anticoagulants, may abort DIC in these pa tients. 76, 90 In an acute situation, simply placing the patient with a LeVeen shunt and DIC in a sitting posi tion will usually stop the shunt function and, at least temporarily, abort the DIC process.
Chronic Disseminated Intravascular Coagulation
Chronic DIC is a compensated event and repre sents the pure end of a clinical spectrum that may not always represent reality. 91 Those conditions that are most commonly associated with a chronic DIC-type process are depicted in Table 6 . Obstetrical accidents are common causes of chronic DIC. The retained fetus syndrome usually represents an acute DIC pro cess; however, many women with a retained dead fetus may develop a chronic-type DIC syndrome that then slowly amplifies into a more fulminant acute process. 92 Likewise, eclampsia represents the straightforward pathophysiologic features of DIC that often remain chronic and often remain organ specific, re maining localized to the renal and placental microcir culation; however, in approximately 10% of women the process may become systemic and may become acute and fulminant. 93, 94 Many patients undergoing hypertonic saline-induced abortion develop a chronic DIC-type process that in some becomes acute and in others remains chronic and compensated until the abortion is completed. 95 Cardiovascular diseases may likewise be associ ated with chronic DIC and on rare occasions patients with acute myocardial infarction may develop a chronic compensated or, alternatively, acute fulminant DICtype process. 96 The mechanisms remain unclear but may simply be due to shock, hypoxia, and acidosis, with resultant endothelial sloughing or activation of the contact activation system via stasis. Peripheral vascular diseases, such as giant cavernous hemangio mas, hereditary hemorrhagic telangiectasia, Leriche's syndrome, and selected small vessel diseases, may lead to a chronic compensated DIC process that may remain chronic or may progress to a more acute phase. 97 ' 98 The vast majority of patients with disseminated malignancy have laboratory findings of a chronic DIC-type process, although many of them never develop specific clinical signs and symptoms of DIC. Pulmonary hemorrhage is a very early and prominent sign of chronic DIC in the patient with cancer. 54, 99 Approximately 75% of patients with cancer and chronic DIC will eventually develop clinical evidence of this syndrome and 25% will develop some type of significant thrombotic event. 1, 2 As will be discussed under "Therapy," many patients with chronic DIC and cancer may show marked correction of both the clinical hemorrhage or thrombosis as well as labora tory findings of DIC when aggressive antineoplastic therapy is instituted. 2,54,100-102 Many hematologic dis orders have also been associated with DIC. Agnogenic myeloid metaplasia has been associated with DIC and likewise a significant number of patients with polycy themia rubra vera have clinical and laboratory find ings of an underlying chronic compensated DIC-type process. 53, 54, 103, 104 There is an increased tendency for thrombosis or thromboembolism in patients with par oxysmal nocturnal hemoglobinuria, and this repre sents a DIC-type process that is clinically manifested primarily as thrombosis. 105, 106 Collagen vascular diseases may also be associated with DIC, and any patient with a collagen vascular disorder, especially when associated with significant small vessel involvement, may develop DIC. This DIC, usually in a chronic compensated form, may be seen in patients with severe rheumatoid arthritis, sys temic lupus erythematosus, Sjogren's syndrome, dermatomyositis, and scleroderma. Again, this is most commonly seen when these disorders are associated with a severe microvascular component. 1, 2, 107 Hemolytic uremic syndrome (HUS) like eclamp sia, shares similar pathophysiologic features with DIC. However, HUS often remains organ specific and lo calized to the renal microcirculation. 108, 109 In approx imately 10% of patients with HUS the syndrome becomes systemic. 2, 76 It should be appreciated that when patients with HUS are seen, it is often clinically impossible to know whether the disease started as a primary insult to the renal vasculature and subsequent activation of the coagulation system or whether there was a primary activation of the coagulation system that initiated a localized or systemic DIC process that then subsequently induced local damage to the renal microcirculation secondary to fibrin deposition. No matter where the process started, the clinical mani festations may be quite similar; more importantly, when a patient with HUS is seen, it is often impossi ble to know where the cycle was initiated.
Numerous miscellaneous disorders have been reported to be associated with DIC, including the allergic vasculitides, such as Henoch-Schonlein pur pura and the other allergic purpuras, sarcoidosis, am yloidosis, chronic ulcerative or inflammatory condi tions, including Crohn's disease, acquired immune deficiency syndrome, ulcerative colitis, and severe dia betes mellitus, especially when associated with a sig nificant microvascular component. [110] [111] [112] In addition, a chronic compensated DIC-type syndrome may occur in patients who have hyperlipoproteinemias types II and IV. 113 On rare occasions, patients may develop a chronic DIC-type process in which no cause can be found. 1, 2, 76 Figure 2 exemplifies how a wide variety of seem ingly unrelated pathophysiologic insults can give rise to the same common final pathway, the syndrome referred to as DIC. There are many disorders associ ated with endothelial damage, circulating antigenantibody complex, endotoxemia, tissue damage of any type (with resultant release of tissue procoagulant materials or tissue procoagulant enzymes), platelet damage and release, or red cell damage. [114] [115] [116] When one of these insults occurs, there are many potential activation pathways that may eventually give rise to systemically circulating plasmin plus systemically cir culating thrombin. When these two enzymes are cir culating systemically, DIC is the usual result. 1, 2, [117] [118] [119] In many instances, the pathways leading from the ini tial pathophysiologic insult to the generation of sys temic thrombin and plasmin are different; regardless of the activation pathway. Once triggered, the resul tant DIC-type pathophysiology remains the same.
PATHOPHYSIOLOGY
The pathophysiologic changes in DIC, once a triggering event has been provided, are summarized in Figure 3 . After the coagulation system has been acti vated and both thrombin and plasmin circulate sys temically, the pathophysiologic changes of DIC are
FIG. 2. A schema of the triggering mechanisms in disseminated intravascular coagulation.
AG-AB: antigen-antibody.
FIG. 3. A schema of the pathophysiologic changes in disseminated intravascular coagulation.
relatively constant in all disorders. When thrombin circulates systemically, it behaves as it would locally and begins to cleave fibrinopeptides A and B from fi brinogen, thus leaving behind fibrin monomers. Most of the fibrin monomers will then polymerize into fi brin (clot) in the microcirculation, leading to micro vascular and macrovascular thrombosis, interference with blood flow, peripheral ischemia, end-organ dam age, and other attendant findings. 1, 2, 76, [120] [121] [122] As fi brin is deposited in the microcirculation, platelets become trapped and the usual attendant thrombocy topenia, typical of DIC, follows. 123, 124 On the other side of the "circle" depicted in Figure 3 it is noted that plasmin also now circulates systemically and behaves as it normally would locally and begins to cleave the carboxy-terminal end of fibrinogen into FDP system ically, thus creating the clinically recognized X, Y, D, and E fragments. [125] [126] [127] [128] It should be noted that plas min also rapidly releases specific peptides, the Bβ 15-42 and related peptides, which also serve as diagnostic molecular markers and will be discussed subsequently. FDP may combine with circulating fibrin monomers before fibrin monomers have polymerized into fibrin.
When these degradation products complex with fibrin monomer, fibrin monomer cannot polymerize and therefore becomes solubilized. This complex of deg radation products and fibrin monomer is referred to as soluble fibrin monomer, which is a significant aid in the diagnosis of DIC. The presence of soluble fi brin monomer forms the basis of the paracoagulation reactions, the ethanol gelation test, or the protamine sulfate test. [129] [130] [131] [132] If one adds protamine sulfate or ethanol to a citrated tube of patient plasma contain ing soluble fibrin monomer, the ethanol or protamine sulfate will clear the FDP from fibrin monomer, fi brin monomer will then complex with other fibrin monomer and polymerize. As a result fibrin strands are formed in the test tube and this is interpreted as a positive protamine sulfate or ethanol gelation test. [133] [134] [135] Thus, systemically circulating FDP inter fere with fibrin monomer polymerization. This, of course, further impairs hemostasis and leads to hem orrhage. An additional biologic activity of degrada tion products is that the later fragments have a high affinity for platelet membranes and coat their sur faces. This often creates a very clinically significant platelet function defect. [136] [137] [138] Thus, when seeing a patient with DIC who has a reasonable platelet count and is only mildly to moderately thrombocytopenic, the clinician should not mistakenly harbor a false sense of security because it must be appreciated that those platelets remaining in the circulation are usually significantly dysfunctional and may lead to, or con tribute to, clinically significant hemorrhage.
Plasmin, unlike thrombin, is a general proteolytic enzyme that has equal affinity for fibrinogen and fi brin. 139, 140 In addition, plasmin also effectively biodegrades many clotting factors, including Factors V, VIII, IX, and XI, and other plasma proteins, includ ing growth hormone, adrenocorticotropic hormone, (ACTH), and insulin. [141] [142] [143] [144] As plasmin degrades cross-linked fibrin, specific FDP appear in the circu lation; one of these is D-dimer, which will be dis cussed subsequently. Additionally, as plasmin circu lates systemically, it often activates both C1 and C3 systemically with the attendant activation of the entire complement sequence leading to C8,9 activation and subsequent cell and platelet lysis. [145] [146] [147] This is of sig nificance clinically in DIC and related syndromes associated with circulating plasmin because the atten dant red cell lysis will release red cell ADP and red cell membrane phospholipid, thus providing more procoagulant material. In addition, complement-in duced platelet lysis will not only cause further throm bocytopenia, but also will provide more platelet procoagulant material. Of additional clinical concern, activation of the complement system will increase vas cular permeability, thus leading to hypotension and shock.
Activation of the kinin system is also an impor tant pathophysiologic event with serious clinical con sequences in DIC and related syndromes. With early activation of the coagulation system, as commonly occurs in DIC, there is usually generation of Factor XIIa, with the subsequent conversion of prekallikrein to kallikrein and subsequent conversion of high mo lecular weight kininogen into circulating kinins. [148] [149] [150] [151] This, of course, also leads to increased vascular per meability, hypotension, and shock.
In summary, as thrombin circulates systemically, the consequences are primarily thrombosis with depo sition of fibrin monomer and polymerized (crosslinked) fibrin in the microcirculation and, at times, large vessels. Concomitantly, plasmin also circulates systemically. This enzyme primarily accounts for the hemorrhage seen in DIC because of the creation of FDP and the interference of these degradation prod ucts with fibrin monomer polymerization and platelet function. Additionally, plasmin-induced lysis of nu merous aforementioned clotting factors also leads to hemorrhage. By appreciating these circular types of pathophysiologic events, it is easy to appreciate why the vast majority of patients with DIC are sustaining hemorrhage plus thrombosis. Clinicians are often mis guided by appreciating only the hemorrhage that occurs in these patients, because this is the most obvi ous physical finding noted during clinical examina tion. However, less often appreciated, but of equal or more importance, is the marked degree of microvas cular thrombosis and, at times, large vessel thrombo sis occurring and leading to end-organ damage, which may be extremely difficult to reverse. Thus, microvas cular thrombosis and subsequent interference with blood flow and end-organ damage are usually not appreciated until laboratory parameters provide a clue to their presence, for example, impending renal fail ure, pulmonary failure, elevated muscle-derived enzymes, liver enzymes, bone enzymes, and severely compromised pulmonary function. Therefore it is important to realize that the majority of patients with DIC are not only undergoing significant hemorrhage, but also significant and often diffuse thrombosis. [152] [153] [154] [155] It should again be emphasized that it is usually throm bosis that is the more irreversible insult and more commonly leads to altered morbidity and mortality due to ischemic changes, end-organ damage, and potential death of the patient. Figure 4 represents selected pathocybernetic events in DIC. These events are depicted for illustra tive purposes; only several events in a DIC episode have been selected. Many others could have been selected to exemplify the all-important point that once a DIC process is initiated, the cybernetic nature of the coagulation system and the DIC process itself is such that the process will continue to self-perpetuate until something is done medically to intervene with the procoagulant drive. 156 For example, if starting with a clinical insult resulting in damaged endothelium, damaged endothelium will subsequently convert Fac-
FIG. 4. A schema of the pathocybernetic events in disseminated intravascular coagulation.
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tor XII to Factor XIIa with the eventual generation of thrombin and the subsequent generation of fibrin; deposition of fibrin on the endothelium will cause more damaged endothelium. Thus, a self-perpetuating cycle is initiated, until stopped. In this selected in stance the damaged endothelium will also lead to platelet release with eventual availability of platelet factor 3, leading to the conversion of Factor X to Factor Xa with the eventual generation of thrombin, more fibrin deposited on the endothelium, and more endothelial damage and more platelet release. Also in this selected instance the damaged endothelium will likely give rise to red cell hemolysis, as may the deposited fibrin, thus giving rise to release of red cell ADP causing more platelet release, more thrombin generation, further fibrin deposition, further endothe lial damage, and further red cell hemolysis. Red cell hemolysis will, of course, also release red cell mem brane phospholipid, which may also give rise to even tual Factor Xa generation, thrombin generation, and fibrin deposition, which, likewise, is associated with more red cell hemolysis and damaged endothelium with attendant red cell hemolysis. Thus, the nature of the process is circular and self-perpetuating; until something is done medically to intervene, the patho physiologic process will continue. Table 7 depicts those clinical situations that may give rise to platelet factor 3 release to possibly initiate or, more impor tantly, perpetuate a DIC-type episode. The presence of subendothelial collagen, epinephrine, circulating antigen-antibody complexes, endotoxin, thrombin, or complement activation (possible through previous plasmin generation) will all cause a platelet factor 3 release and continue to augment a DIC process. [157] [158] [159] [160] In addition, but less likely, any one of these may inde pendently cause a platelet factor 3 release that may initiate rather than simply perpetuate a process of DIC. However, it is likely that the availability of platelet factor 3, by any of the aforementioned poten tial mechanisms, is probably more important as an accelerating and self-perpetuating process rather than a strictly etiologic singular mechanism in the initiation of DIC. Table 8 depicts the consequences of endotoxemia in initiating DIC. Endotoxin (bacterial coat lipopolysaccharide) is capable of inducing a granulocyte release of procoagulant or coagulation-activating enzymes, of directly converting Factor XII to Factor XIIa, may induce a platelet release reaction, and may cause en dothelial sloughing with subsequent exposure of sub endothelial collagen. [161] [162] [163] [164] [165] [166] Any one of these insults may independently initiate an episode of acute DIC; however, what is most likely clinically seen is a sum mation of several or all of these events in patients with endotoxemia and DIC. Table 9 depicts the clinical consequences of activating Factor XII to Factor XIIa in an episode of DIC. When Factor XIIa is circulating, there may be activation of the fibrinolytic system via mechanisms previously discussed. Subsequent to this there will be plasmin-induced biodegradation of numerous coagu lation factors and the clinical manifestations of this will be hemorrhage. Secondly, the generation of Fac tor XIIa may lead to kinin activation with attendant vasodilation and the resultant clinical manifestations of hypotension and shock. [167] [168] [169] [170] [171] Thirdly, as Factor XIIa circulates and activates the fibrinolytic system, there will be subsequent activation of the complement system with cell lysis, vascular changes, and a plate let release reaction. 172, 173 Platelet release will likewise provide more coagulant material to self-perpetuate the intravascular clotting process; the vascular changes of complement activation are comprised of increased vascular permeability, again leading to hypotension and shock. Clinical situations that may give rise to endothe lial damage, endothelial sloughing with exposure of subendothelial collagen and subendothelial basement membrane, and the subsequent activation of Factor XII to Factor XIIa and possibly XI to XIa are: viremias (presumably the mechanism is circulating an tigen-antibody complex), heat stroke, patients with hyperacute renal allograft rejection, circulating an tigen-antibody complexes of any origin, shock with attendant hypoxia and acidosis, endotoxemia, and very importantly ongoing DIC with subsequent vascu lar damage. [174] [175] [176] [177] [178] Many of the pathophysiologic events in DIC, as previously discussed, will give rise to significant endothelial damage with endothelial sloughing and the exposure of subendothelial collagen and basement membrane and subsequent activation of Factor XII to Factor XIIa and possibly Factor XI to Factor XIa, thus, again, self-perpetuating the DICtype process.
CLINICAL FINDINGS
The general signs and symptoms of DIC can be highly variable and generally consist of fever, hypo tension, acidosis, proteinuria, and hypoxia. 1, 2, 76, 179 These findings are rather general signs and symptoms and may be found in many disorders and are not par ticularly helpful from the diagnostic standpoint. How ever, more specific signs found in patients with DIC that should immediately alert one to the possibility of DIC in the appropriate clinical settings are depicted in Table 10 and consist of petechiae and purpura, which are found in the vast majority of patients with DIC, hemorrhagic bullae, acryl cyanosis and, at times, frank gangrene. 1, 2, 76, [179] [180] [181] [182] [183] [184] [185] In addition, wound bleed ing, especially oozing from a surgical or traumatic wound, is an extremely common finding in patients with DIC. 1, 2 Oozing from venipuncture sites or intra arterial lines is an additional common finding. 2 Large subcutaneous hematomas, as well as deep tissue bleeding are also frequently seen. 2, 76 The average patient with acute DIC usually bleeds from at least three unrelated sites. 1, 2, 76, 179 For example, the patient may have petechiae and purpura, oozing from intra venous sites, and massive gastrointestinal blood loss or may have petechiae and purpura, massive hemop tysis, and hematuria. At times, other types of bleed ing may also occur in deep tissues, including intracra nial bleeding and intramuscular hemorrhage with compartmental compression syndromes. Any combi nation of bleeding sites can be seen, and it is unclear as to why different patients will bleed from differing sites. A significant amount of microvascular thrombo sis and, at times, large vessel thrombosis may occur in DIC and may not be clinically obvious unless and until looked for. 2, 76, 179, 186, 187 Table 11 depicts the incidence of end-organ dysfunction in DIC, these findings representing microvascular thrombosis of tis sues with resultant ischemia and hypoxia rather than end-organ hemorrhage. Those organ systems that have a high incidence of microvascular thrombosis associ ated with subsequent end-organ dysfunction include cardiac, pulmonary, renal, and central nervous system dysfunction. 2188 Thrombotic thrombocytopenic pur pura (TTP) is commonly associated with central ner vous system dysfunction; however, it should be realized that this clinical finding can be seen just as commonly in acute disseminated intravascular coagulation. 189 
MORPHOLOGIC FINDINGS
Morphologic findings in DIC are summarized in Table 12 and consist of characteristic but not patho gnomonic peripheral smear findings as well as hemor rhage in any organ or combination of organs. 190, 191 Any organ may be associated with severe hemorrhage ' 191 These are usually seen in association with intense va soconstriction, presumably due to compounds released from platelets, including biogenic amines, adenine nucleotides, and kinins. 192 These are later replaced by hyaline-rich microthrombi. 190, 191 In addition, another early finding is that of fibrin monomer deposition, primarily in the reticuloendothelial system; these find ings require special staining. 193 Later findings in pa tients with acute DIC are the typical fibrin-rich hya line microthrombi that are thought to replace earlier deposited platelet-rich microthrombi and fibrin mono mer deposits. 194 ' 195 In addition, many patients with acute DIC develop typical pulmonary hyaline mem branes that account, in part, for the significant degree of pulmonary dysfunction and hypoxemia seen in these patients. 76, 196, 197 In this regard it should be noted that pure adult shock lung syndrome is most likely an organ-specific DIC-type pathophysiologic event that usually remains localized to the pulmonary bed. 2 Pe ripheral smear alterations typically seen in DIC are depicted in Table 13 . Schistocytes are red cell frag ments, including typical so-called Heilmeyer helmet cells, which are seen in approximately 50% of patients with acute DIC. 112, 113, 198, 199 Schistocytes are shown in Figure 5 . The mechanisms for the formation of schis tocytes in acute DIC have been elegantly demonstrated by Bull and associates, 200, 201 who described fibrin-red cell interactions. It is to be emphasized that the ab sence of schistocytes can certainly not be used to rule out a diagnosis of acute DIC, since they only occur in 50% of patients. The majority of patients with acute DIC will also present with a mild reticulocytosis and a mild leukocytosis, usually associated with a mild to moderate shift to immature forms. The degree of thrombocytopenia that is usually present in most in stances of acute DIC is often obvious by examina tion of the peripheral blood smear. 202, 203 In addition, many so-called large bizarre platelets representing young platelets are usually seen on the peripheral smear in patients with DIC; this finding most likely simply represents an increased population of young platelets due to increased platelet turnover and de creased platelet survival due to platelet entrapment in microthrombi. 204, 205 Platelet-rich microthrombi are early findings in patients with DIC and are often easily demonstrated in the pulmonary microcirculation where they are usu ally seen in association with intense vasoconstriction due to vasoconstrictive compounds released from platelets. It is thought that these platelet-rich micro thrombi are later replaced by more typical hyalinerich microthrombi. 190, 191, 206 Fibrin monomer may also be precipitated early in DIC, but this is not com monly appreciated, since fibrin monomer is not dem onstrated with usual staining techniques and requires periodic acid -Schiff (PAS) staining after ethanol fix ation of appropriate tissue. Fibrin monomer is most commonly precipitated in the reticuloendothelial sys tem. The precipitation of fibrin monomer may cause significant end-organ damage due to primary cellular or tissue damage as well as to microvascular occlu sion. In addition, with this precipitation will come impaired reticuloendothelial clearance of FDP, acti vated clotting factors, and circulating soluble fibrin monomers.
Typical hyaline microthrombi occurring later in an episode of DIC and commonly accounting for sig nificant end-organ damage are of three types. First, globular hyaline microthrombi may be seen on the peripheral blood smear and comprised of highly po lymerized complexes of FDP and many intermedi ates. 190, 207 These may be from 4 to 60 µ 3 in volume and may occur singly or in mass and may be noted on a peripheral smear stained with PAS. They are also seen intravascularly but rarely appear to occlude the microcirculation. Another type is the typical intravas cular hyaline microthrombus so typically seen by pa thologists at postmortem examination in patients with DIC. 190, 208, 209 It should be pointed out, however, that these microthrombi are not pathognomonic for DIC and may be seen in other related disorders, including TTP. 189, 210 These intravascular hyaline microthrombi are homogeneous, compact, intravascular hyaline struc tures that are oriented parallel to the blood flow and occasionally are noted to contain platelets or white cell fragments. They are easily seen by PAS, trichrome, tryptophan, and fluorescein-labeled antifibrinogen antiserum staining and are readily seen by electron mi croscopy. [211] [212] [213] Third, pulmonary hyaline mem branes are also a form of hyaline microthrombus and consist of highly polymerized complexes of FDP and all types of intermediates. 214, 215 They are usually seen to cover the alveolar epithelium with a preference of areas that have been denuded of epithelial cells. In addition, the interalveolar capillaries beneath these hyaline membranes often show abnormal vascular permeability with the circulation of endothelial cells, plasma protein precipitation between endothelial bor ders, and the formation of interstitial edema.
It should be appreciated that many patients with DIC develop these pulmonary hyaline membranes, which may account for significant pulmonary failure, abnormal arterial blood gases, and pulmonary func tion tests, including markedly altered diffusion capac ity. In addition, it should be emphasized that so-called pure adult shock-lung syndrome shares similar patho physiologic features with acute DIC and in this par ticular instance the pathophysiologic events appear to remain localized to the pulmonary microcirculation rather than becoming a systemic process. 216 ' 217 How ever, the pulmonary hyaline membranes of adult shock-lung syndrome and those seen in DIC are iden tical. For that matter, the pulmonary hyaline mem branes seen in pediatric respiratory distress syndrome are also comprised of the same material, highly poly merized complexes of fibrin(ogen) and FDP. In this particular clinical situation the pathophysiologic pro cess also remains much the same as in systemic DIC. This phenomenon has recently been carefully studied and reviewed by Ambrus and coworkers [218] [219] [220] and it appears that in the normal infant during normal deliv ery a short period of hypoxia occurs and concomitant with this is endothelial sloughing with the usual pre cipitation of fibrin, which is then removed by subse quent activation of the fibrinolytic system. However, in patients with pediatric respiratory distress syndrome this physiologic event may be altered. In infants born of diabetic mothers the same process occurs, with deposition of polymerized complexes of fibrinogen and fibrin; however, in these infants there are elevated levels of alpha2-macroglobulin, which appear to in hibit the ability of the fibrinolytic system to degrade these deposits and hence a resultant "hyaline mem brane." 221 A similar pathophysiologic state appears to exist in the premature infant, and in this case there is hypoplasminogenemia and thus a hypoactive fibri nolytic system available for activation and therefore fibrin(ogen) deposition continues unchecked with no ability to resolve this and a pulmonary "hyaline mem brane" results. 222, 223 Understanding the pathophysio logic changes of pediatric respiratory distress syndrome has led to the relatively successful use of plasminogen concentrates in infants with pediatric respiratory dis tress syndrome. Figure 6 depicts hyaline membranes as well as pulmonary edema in an infant dying with DIC secondary to meningococcemia.
As previously emphasized, DIC is a process asso ciated with hemorrhage and thrombosis, although thrombosis is less clinically evident and less commonly appreciated by the clinician until late in a course of DIC or until autopsy is performed. However, hemor- rhage may often be successfully contended with in patients with DIC, whereas thrombosis in the micro circulation and macrocirculation often leads to endorgan damage with irreversible ischemic changes that may result in death of a patient. It is therefore useful to examine those parameters that may accelerate or, indeed, cause precipitation of microthrombi and macrothrombi in patients with DIC. Identifiable precipi tating causes for acceleration or induction of microthrombi are depicted in Table 14 . It will be noticed that an important cause of acceleration of or precip itation of thrombi in the circulation are vasomotor reactions, including elevated catecholamines and pro gressive acidosis. 224, 225 In addition, glucocorticoids or ACTH elevation may also contribute to the precipita tion of microthrombi in patients with DIC, and thus careful thought must be given to the use of steroids in these patients, although in many instances steroid use is indeed warranted. 2, 76, 226 In addition, if there is impaired reticuloendothelial clearance, due to fibrin monomer precipitation or the use of steroids, of FDP, circulating soluble fibrin monomers, or activated co agulation factors (especially Factor Xa or thrombin), this could also markedly enhance the precipitation of microthrombi. 2, 227 Additionally, if there is impaired fibrinolytic system activation, this may also lead to accelerated fibrin deposition throughout the circula tion. 2, 228 All of these mechanisms, as well as many interplays between them, may lead to accelerated fi brin monomer precipitation in the micro-and macrocirculation with attendant end-organ damage that may be irreversible and lead to significant morbidity and mortality. 2, 76 When seeing a patient with DIC, it should be appreciated that these potential mechanisms and their interplays may be operative and should be kept in mind.
CLINICAL FINDINGS OF CHRONIC DISSEMINATED INTRAVASCULAR COAGULATION
The clinical findings of chronic DIC are often significantly different from those in patients with acute DIC. Patients with chronic DIC more com monly have bothersome bleedings and diffuse throm boses rather than acute fulminant life-threatening hemorrhages. 189, 229 These patients have been appro priately described as having "compensated DIC." 230, 231 In this instance there is usually an increased turnover and decreased survival of many components of the hemostasis system, including the platelets, fibrinogen, and Factors V and VIII. Because of this, most coag- However, patients with chronic DIC almost uni formly have significantly elevated FDP leading to impairment of fibrin monomer polymerization and a clinically significant platelet function defect resulting from the coating of platelet membranes by FDP. Thus, patients with chronic DIC commonly present with findings of gingival bleeding, easy and spontane ous bruising, large cutaneous ecchymoses, and mild to moderate mucosal membrane bleeding often mani fested as genitourinary or gastrointestinal hemor rhages. However, patients may also present with dif fuse or singular thromboses, which are quite taxing with respect to clinical management.
LABORATORY ABNORMALITIES IN DISSEMINATED INTRAVASCULAR COAGULATION
With the complex pathophysiologic changes de picted previously, the laboratory findings of DIC may be highly variable, complex, and difficult to interpret unless the pathophysiologic mechanisms of this dis order are clearly understood. Likewise, the evalua tion of patients with DIC, especially with respect to significant laboratory tests that are useful for aiding in a diagnosis, as well as for monitoring efficacy of therapy, remain highly confusing and in some in stances controversial. To complicate the situation fur ther, many newer modalities have become available for assessing the patient with DIC; however, many of these modalities are as yet without enough experi ence to determine how clinically applicable they may be. 76, 110, [232] [233] [234] [235] This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
The prothrombin time should be abnormal in the vast majority of patients with DIC for multiple rea sons. Firstly, the prothrombin time depends on the ultimate conversion of fibrinogen to fibrin and in DIC there is usually hypofibrinogenemia, FDP interference with fibrin monomer polymerization, and thrombin interference with fibrin monomer polymerization. Additionally, plasmin-induced lysis of Factors V and X, to which the prothrombin time should be sensi tive, is often present. In reality, the prothrombin time is prolonged in approximately 75% of patients with acute DIC and in 25% of patients the prothrombin time is normal or supernormal. The reasons for this are explained as follows: If there is the presence of a circulating activated clotting factor or factors, such as thrombin or Factor Xa, this may accelerate the for mation of thrombin and the subsequent conversion of fibrinogen to fibrin in the test system and thus render a normal or supernormal result, even though some co agulation factors to which the prothrombin times are sensitive may be extremely low. In addition, early deg radation products may be rapidly clottable by throm bin and quickly "gel" the test system, rendering a nor mal or supernormal prothrombin time. 1, 2, 76 For these reasons, the prothrombin time is generally an unreli able and minimally useful test in DIC patients.
The activated partial thromboplastin time (APTT) should also be prolonged in acute DIC for multiple reasons. Finally, there is effective plasmin-induced biodegradation of many clotting factors to which the APTT is sensitive, including Factors V, VIII, IX, and XL The APTT, like the prothrombin time, is sensitive to (prolonged by) fibrinogen levels which are less than 100 mg/dl. The prothrombin time or activated throm boplastin time begins to prolong at a fibrinogen level of approximately 100 mg/dl or less. Additionally, the APTT should (at least theoretically) be prolonged because of FDP inhibition of fibrin monomer poly merization. However, the APTT is prolonged in only 50 to 60% of patients with acute DIC and therefore a normal APTT can certainly not be used to rule out a diagnosis of acute DIC. The reasons for a supernor mal or normal APTT in 40 to 50% of patients are as follows: firstly, early degradation products may be rapidly thrombin clottable and gel the test system, rendering a supernormal result; secondly, and perhaps more commonly, circulating activated clotting factor or factors are usually present in patients with acute DIC and activated clotting factors, especially circulat ing Factor Xa or circulating thrombin, may bypass the necessity of other clotting factors being measured in the APTT system, thus leading to rapid conversion of fibrinogen to fibrin and a supernormal test. 1 
' 2 ' 76
Like the prothrombin time, the APTT is of marginal usefulness in patients with DIC.
The thrombin time and reptilase time are expected to be prolonged in patients with acute DIC. Both of these tests should be prolonged by the presence of cir culating FDP and interference with fibrin monomer polymerization and from the hypofibrinogenemia commonly present in acute DIC. 39, 136, 222, [236] [237] [238] In fact, both of these tests are generally prolonged in patients with DIC; however, for reasons previously mentioned, they may be normal or supernormal in isolated cases. An additional bonus test may be derived from either one or both of these tests by observing the resultant clot for absence or presence of clot lysis. 76 Since many small nonhospital laboratories do not have facilities for assessing the fibrinolytic system, this sim ple nonquantitative tool may provide significant clin ical information. Thus, instead of throwing away the thrombin time or reptilase time derived clot, the tube can be set aside for 5 to 10 minutes and observed at the end of this time for evidence of clot dissolution. If the clot is not dissolving in 10 minutes, it may be assumed that the amount of plasmin circulating is not clinically significant; however, if the clot begins to lyse within this period, a clinically significant amount of plasmin is likely to be present.
The platelet count is usually significantly decreased in patients with acute DIC; however, the range may be quite variable and may be as low as 2000 to 3000 mm 3 or may be greater than 100,000 mm. 3 However, in most patients with acute DIC the degree of throm bocytopenia is usually obvious by examination of a peripheral smear and averages around 60,000 mm. 3 Virtually all tests of platelet function, including the template bleeding time, platelet aggregation, and plate let lumiaggregation, will be abnormal in patients with DIC. This primarily occurs because of FDP coating of platelet membranes; there may be other potential reasons for platelet dysfunction as well, such as par tial release of platelet procoagulant materials. Thus, there is no reason for performing tests of platelet function in patients with acute DIC, since abnormal results will invariably be found and add little to the diagnosis. It should be mentioned that no typical aggregation or lumiaggregation is noted in DIC and a wide variety of different types of aggregation and re lease defects may be seen in different patients. 2, 136, 232 Coagulation factors assays will provide little, if any, clinical useful information in patients with DIC. In the majority of patients with acute DIC there is presence of systemically circulating activated clot ting factor, especially Factors Xa, IXa, and throm bin. 2, 239, 240 Thus, coagulation factor assays done by the standard APTT-derived or prothrombin timederived laboratory techniques using deficient sub strates will render uninterpretable and meaningless results in patients with DIC. For example, if a Factor VIII assay were attempted in the presence of circulat ing Factor Xa in a patient with DIC, a high level of Factor VIII would be recorded, since Factor Xa "bypasses" the necessity for Factor VIII:C in the test system, 2,76,241-243 and a rapid conversion of fibrino gen to fibrin will be noted. Thus, a rapid time will be recorded on the typical standard curve and this will be interpreted as a high Factor VIII level when there may, in fact, be no Factor VIII present. Thus, factor assays will render erroneous and meaningless results and are virtually uninterpretable and certainly add lit tle or nothing to the diagnosis in patients with DIC. 76 FDP are elevated in 85 to 100% of patients with acute DIC, depending on the series re ported. 2, 136, 232, 244, 245 It is a common misconception that elevated FDP titers are diagnostic of DIC, and it should be recalled that these degradation products are only "diagnostic" of plasmin biodegradation of fibrin ogen or fibrin and FDP are therefore only indicative of the presence of plasmin. Their method of forma tion is depicted in Figure 7 . The possibility of falsenegative results in some patients with DIC will be dis cussed subsequently.
The protamine sulfate test or ethanol gelatin test for circulating soluble fibrin monomer is almost al ways positive in acute and chronic DIC. 2, 129, 136, [246] [247] [248] [249] These are highly useful tests. Like the FDP, however, neither is diagnostic, since both elevated FDP and cir culating soluble fibrin monomer can be noted in other clinical situations, including women using oral con traceptives, patients with pulmonary emboli, selected patients with myocardial infarction, patients with cer tain selected renal diseases, and patients with arterial or venous thrombotic or thromboembolic events. 250, 251 On occasion, the protamine sulfate test or ethanol gel ation test may be negative for reasons to be discussed. In these rare instances, after successful therapy, the test may become positive for a short period of time and then revert to negative. 2, 76 The protamine sulfate test as described by Kidder et al 252 appears to be the most sensitive and clinically applicable test for detect ing circulating soluble fibrin and is the one used by my laboratory.
The antithrombin III (AT III) determination has become a key test for aiding in the diagnosis and monitoring of therapy in patients with acute and chronic DIC. [253] [254] [255] In DIC there is almost always an overwhelming generation of activated clotting factors (serine proteases) during the activation (triggering) process as well as during the ongoing intravascular co agulation event. When this occurs, there is an irrevers ible complexing of some circulating activated clotting factor with AT III, thus leading to significant de creases of functional AT III in the majority of pa tients with acute and chronic DIC. 254, [256] [257] [258] [259] [260] In addi tion, as will be discussed in subsequent sections, the determination of an AT III assay provides one of the few reliable modalities for monitoring efficacy of anticoagulant therapy in patients with DIC. Several recent studies have compared the clinical applicability of various AT III methodologies, and, based on these studies synthetic substrate assay methods are clearly the methods of choice. [261] [262] [263] Immunologic assays for AT III ignore biologic function and may be normal or low. Just because AT III is complexed with a serine protease does not necessarily mean the antigenic determinants, as measured by immunologic assays, are no longer present. Thus, immunologic assays for AT III in patients with DIC should not be used. 2 Increased platelet turnover and decreased plate let survival will usually be seen in patients with DIC. 264, 265 However, since thrombocytopenia is often present, this method of following patients may be of questionable significance, especially in severely throm bocytopenic patients. It has been found that simple methods using automated electronic counting tech niques have proved useful in monitoring efficacy of
FIG. 7. A depiction of the method of formation of fibrin(ogen) degradation products.
This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. therapy in patients with chronic DIC provided the platelet count is greater than 80,000/mm 3 . 266 Platelet factor 4 levels and β-thromboglobulin levels are newer assay techniques that are markers of overall platelet reactivity and release. As such, several recent reports have suggested that either one of these two modalities may be highly useful in aiding in a diagnosis of DIC as well as in monitoring efficacy of therapy with respect to blunting or causing cessation of the intra vascular clotting process. [266] [267] [268] [269] [270] [271] Both assays are now readily available for the clinical laboratory and each has its attendant advantages and disadvantages. Both platelet factor 4 and /3-thromboglobulin are elevated in the vast majority of instances of DIC; however, it should be readily appreciated that neither of these modalities is diagnostic of DIC, since they may be ele vated in a wide variety of intravascular coagulation disorders, including pulmonary emboli, acute myocar dial infarction, deep vein thrombosis, and in many disorders associated with microvascular disease, such as diabetes and autoimmune disorders. 272, 273 How ever, if they are noted to be elevated in the patient with DIC and then decline after the institution of spe cific therapy, this may provide a useful sign that ther apy has been successful in either blunting or stopping the intravascular clotting process.
Fibrinopeptide A is commonly elevated in pa tients with DIC and is an overall assessment of hemostasis, much like platelet factor 4 and /3-thromboglobulin levels. The presence of fibrinopeptide A is diagnostic of the presence of thrombin acting on fi brinogen. Fibrinopeptide A determinations may be of aid in assessing efficacy of therapy, as has been sug gested in several studies. 186, [274] [275] [276] [277] [278] However, the deter mination of fibrinopeptide A is presently laborious for the routine clinical laboratory and is not diagnos tic of DIC, since it may be elevated in a wide variety of other micro-or macrovascular thrombotic events, as previously discussed. Nonetheless, the noting of high fibrinopeptide A levels followed by a decline of these levels with the institution of therapy may be a good prognostic sign with respect to stopping or blunting the intravascular clotting process. A newer modality, also available by radioimmunoassay, is that of Bβ 15-42 and related peptide determinations. [279] [280] [281] The noting of elevated Bβ 15-42 and related peptides may, when performed in conjunction with concomi tant fibrinopeptide A levels, add greatly to the differ ential diagnosis of DIC versus primary lysis. As previ ously discussed, plasmin will rapidly cleave Bβ peptides at position 118 and position 42, and 15 through 42 (after thrombin has cleaved fibrinopeptide B or amino acid sequence 1 through 14) off of the Bβ chain of fi brinogen. Thus, the elevation of Bβ 15-42 related pep tides in the absence of fibrinopeptide A is strong evi dence for primary fibrinolysis, whereas the elevation of both fibrinopeptide A and Bβ 15-42 related pep tides is strong evidence of DIC. Formation of Bβ 15-42 peptides is summarized in Figure 8 .
Fibrinolytic system assays are now readily avail able in the clinical laboratory and provide highly use ful information in patients with DIC. Typically there are decreased plasminogen levels and circulating plas min present. 1, 2, 14, 145, 282 The presence or absence of a secondary fibrinolytic response is of clinical value in predicting the degree of potential microvascular thrombosis and resultant irreversible end-organ dam age in patients. If there is inadequate or absent acti vation of the fibrinolytic system, the degree of mor bidity and mortality due to end-organ damage may be expected to be greater. The degree of fibrinolytic sys tem activation can be assessed by measuring plasmin ogen and plasmin levels by currently available syn thetic substrate techniques. [283] [284] [285] [286] [287] In this regard, the euglobulin lysis time provides little or no clinical useful information with respect to assessing the fibrinolytic system in clinical disorders, including DIC. 2, 288, 289 The preparation of a euglobulin fraction, by defini tion, destroys fibrinolytic inhibitors and thus a posi tive result is of questionable clinical meaning and may simply represent an artifact. Thus, this test should not be used in clinical medicine. The measurement of fi brinolytic inhibitors, including fast-acting alpha 2antiplasmin [290] [291] [292] [293] [294] and slow-acting alpha 2 -macroglobulin, [295] [296] [297] may also be of help in assessing the overall fibrinolytic system in DIC patients. If these two fibrinolytic system inhibitors are markedly ele vated, there may be an inadequate fibrinolytic This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. response with resultant enhanced fibrin monomer pre cipitation, fibrin deposition, and microvascular or macrovascular thrombosis. Recently, assays for tissue (endothelial) plasminogen activator and tissue plas minogen activator inhibitor have become available; with experience, this determination may also become useful in patients with DIC.
Fibrinogen chromatography may provide a new and sensitive modality for assessing patients with DIC and may prove useful for both aiding in a diagnosis and allowing detailed monitoring of efficacy of ther apy in these patients. 282, [298] [299] [300] [301] Although this modality is currently only used in large centers specializing in thrombohemorrhagic disorders, it has provided quite impressive data and may become clinically applicable in the future, as will be discussed subsequently.
By understanding the pathophysiologic aspects of DIC, it is quite clear that hemostasis will be consider ably altered and thus most common laboratory tests of hemostasis will be significantly abnormal. 76, [302] [303] [304] It is therefore useful to determine which tests are of practical significance with respect to providing a high degree of reliability as well as availability in assessing patients with DIC. In this regard, hospital laborato ries must be equipped to offer assays that will quickly and reliably allow assessment of patients with DIC. If the laboratory is unable to meet this need, the hospi tal is providing substandard medical care by allowing admissions of patients with DIC or diseases associated with DIC. Tests useful for aiding in a diagnosis of DIC are depicted in Table 15 . Tests that are routinely used by me for both aiding in a diagnosis of DIC and monitoring efficacy of therapy in these patients are indicated by an asterisk. 2, 76, 238, 239, 305 In general, I do not indulge in "DIC panels" and prefer to let the par ticular clinical situation, in conjunction with clinical judgment, dictate which laboratory tests are to be obtained both initially and subsequent to therapy. However, if a true "DIC panel" were to be devised, those tests that are indicated by an asterisk would be the recommended current tests for aiding in a diagno sis and monitoring efficacy of therapy because they are readily available and reasonably reliable when evaluated together. However, it must be stressed that none of these tests is diagnostic of DIC and, as in all areas of clinical medicine, laboratory modalities must be evaluated in the appropriate clinical setting. In addition, most of these laboratory tests are certainly not specific. The presence of soluble monomer is one of the more specific tests but certainly not diagnostic. If circulating soluble fibrin monomer is present, as detected by the protamine sulfate test or ethanol gel ation test, this is strong evidence that thrombin and plasmin have circulated. Since fibrin monomer is created by the presence of thrombin and fibrin mono mer has to then be solubilized by complexing with FDP created by plasmin, this test determines the pres ence of both enzymes. A newer diagnostic test for the presence or absence of DIC is the D-dimer assay. D-dimer is a neoantigen formed when thrombin initiates the tran sition of fibrinogen to fibrin and also activates Factor XIII to cross-link the fibrin thus formed; this neoan tigen is formed as a result of plasmin digestion of cross-linked fibrin. 281, 306 The D-dimer test is there fore specific for fibrin degradation products, whereas the formation of FDP, the X, Y, D, and E fragments discussed previously, may be either fibrinogen or fi brin derived, following plasmin digestion. Recently, monoclonal antibodies have been harvested against the D-dimer neoantigen DD-3B6/22, and these have been found to be specific for cross-linked fibrin deriv atives containing the D-dimer configuration. 307 ' 308 The formation of D-dimer is depicted in Figure 9 .
After the harvesting of monoclonal antibodies, a latex agglutination procedure, utilizing latex particles coated with anti-DD-3B6/22 antibody has been devel oped into a commercially available test kit. Recent studies have shown the monoclonal antibody test, per formed by enzyme immunoassay, to be essentially equivalent to the latex agglutination assay, thus mak- ing the latex agglutination assay applicable for mea suring D-dimer in plasma, resulting in a clinically applicable and easily performed test in patients with DIC. 309 We have recently used this assay as part of our laboratory battery of DIC tests to assess its effi cacy in diagnosing patients with suspected or diag nosed DIC. 310 In our studies we have noted that in patients with documented DIC the D-dimer assay was abnormally elevated (more than 200 ng/ml) in 93.2% of patients, with the mean D-dimer level being 2047 ng/ml. In those patients in whom DIC was ruled out, the average D-dimer assay was only abnormal in 6%, with the mean level being 541 ng/ml (Table 16 ).
In addition, the D-dimer assay appears to be of use in patients with deep vein thrombosis. In our experience, the D-dimer assay is abnormally elevated in 42% of patients with deep vein thrombosis, with the average level being 325 ng/ml. Based on our lab oratory evaluation of the D-dimer assay performed by latex agglutination technique, it appears to be a highly useful assay for assessing the probability of DIC in appropriate clinical settings. Indeed, of the usual tests used in assessing patients with DIC, it appears to be the most reliable test with respect to probability of being abnormal in patients with confirmed DIC. In our hands with our battery of DIC tests, in the appro priate clinical setting, the reliability of tests used, in descending order of reliability are the D-dimer assay (abnormal in 93%), the AT III level (abnormal in 89%), the fibrinopeptide A level (abnormal in 88%), and FDP titer, which is usually abnormal in 75% of patients. Lane and coworkers 311 have studied the Ddimer fragment in nine patients with DIC and found the levels to be elevated in eight of the nine. In addi tion, Elms and coworkers 312 have also performed Ddimer assays in DIC patients and found the D-dimer levels to be elevated in all patients with DIC so studied.
It seems reasonable to conclude that the D-dimer latex agglutination test, measuring the presence of the neoantigen DD-3B6/22, is becoming a highly useful test that is easily performed in a clinical laboratory and should be considered in the armamentarium of tests used to confirm or rule out DIC. Since the Ddimer test provides the same information as the com bination of the FDP titer and the protamine sulfate or ethanol gelation test, it can easily replace both of these tests in the diagnostic work-up of a patient with suspected DIC, thus leading to cost effectiveness as well as enhanced efficacy. Table 17 depicts biologic AT III levels in a series of patients with acute and chronic DIC. 76, 257 It will be noted that the vast majority of patients display sig nificant decreases in AT III levels at the time of diag nosis. One exception to this are patients with dissemi nated malignancy and concomitant DIC. In some instances it appears that AT III, as an alpha 2globulin, behaves as an acute phase reactant and may be consumed (complexed) to normal or near-normal levels in patients with disseminated malignancy and concomitant DIC. 2, 53, 54, 313, 314 However, in most all other instances of acute or chronic DIC this serine protease inhibitor appears to be significantly and rap idly decreased. Also, protein C, protein S, and fibronectin levels are decreased in patients with DIC; how ever, their diagnostic efficacy as well as usefulness to monitor therapeutic efficacy remains to be estab lished. 315 ' 316 Figure 7 depicts fibrinogen and its degradation products, the X, Y, D, and E fragments. As previ ously discussed, fibrinogen is comprised of Aα, Bβ, and γ chains and plasmin first digests along the carboxy-terminal of the Aα chain, giving rise to frag ment X. Following this, there is asymmetric digestion by plasmin along the amino-tefminal end of all three chains, giving rise to a fragment Y and a fragment D. Subsequently, fragment Y is further asymmetrically digested on the opposing amino-terminal portion, giv ing rise to another fragment D and a fragment E, or so-called N-terminal disulfide knot. This Figure re veals that fragments X and Y still contain fibrinopeptides, and they are thus thrombin clottable. Un derstanding this and the method of plasmin-induced digestion allows an understanding as to why, in se lected instances, in patients with acute or chronic DIC FDP titers may be negative. The currently available FDP determinations utilize latex particles that are antifibrinogen, and, since they are antifibrinogen, thrombin clot tubes are supplied to clot out fibrino gen so that latex particles will not react with fibrino gen and erroneously measure fibrinogen rather than its degradation products. [317] [318] [319] However, fibrinogen and its degradation products have common antigenic determinants. 320 When these thrombin clot tubes are used, not only is fibrinogen removed from the system, but also fragment X and fragment Y. For this reason, currently available FDP methodologies measure frag ments D and E. Thus, in some instances of DIC when there may be minimal secondary fibrinolytic response and minimal plasmin circulating, there may only be degradation to the X fragment stage or some interme diate between fibrin(ogen) and fragment X. In this instance there may be nothing for the test to measure, since fragment X and its intermediates may be re moved from the test system by the thrombin clot tubes used. Alternatively, in instances of acute DIC in which there is a massive secondary fibrinolytic acti vation and overwhelming amounts of plasmin circu lating, there may be degradation past the D and E stages. Fragments D and E are the last degradation products that have antigenic determinants and that are capable of being detected by the currently avail able commercial FDP titer kits. An additional prob lem is that of massive release of granulocyte enzymes, collagenases and elastases, which may also degrade all available D and E fragments and again render nega tive FDP titers in patients with acute DIC. 76, 321 Thus, the presence of negative FDP titers cannot be used to rule out a diagnosis of acute or chronic DIC. Despite these difficulties, FDP titers are almost always ele vated in patients with DIC. Table 18 depicts those subspecies of fibrinogen and its degradation products that can be readily de tected by fibrinogen chromatography. If there is an increase in high molecular weight fibrinogen com plexes, the presence of thrombin can be assumed. Alternatively, when noticing an increase in concentra tion of early fibrinogen "first derivative," it can be assumed that plasmin is present. The concentrations of these two derivatives in conjunction with elevated FDP can lead to significant information with respect to aiding in a diagnosis and monitoring of therapy in DIC. For example, if thrombin plus plasmin are cir culating in early DIC, both high molecular weight fi brinogen complexes and fibrinogen "first derivative" will be seen. As the thrombotic events begin to sub side, high molecular weight polymerized complexes will begin to decrease, and as the fibrinolytic system becomes activated and plasmin begins to cleave fibrin ogen into lysed fibrin deposited in the microcircula tion, fibrinogen "first derivative" concentrations and FDP will begin to increase, providing a sensitive method for monitoring efficacy of therapy. Clinical information provided by fibrinogen chromatography is summarized in Table 19 . Typical laboratory findings of chronic DIC are significantly different from those seen in acute DIC; many usual tests of hemostasis are normal or near normal and typical findings in chronic DIC are de picted in Table 20 . The platelet count is usually within normal limits or borderline in the patient with chronic DIC; however, most of these patients develop de creased platelet survival and increased turnover of platelets due to platelet consumption, and this is often referred to as a "compensated state." Like the plate let count, fibrinogen levels are usually "compensated"; there is increased turnover and decreased survival of fibrinogen as well as Factor V, Factor VIII, and other coagulation proteins. Thus, fibrinogen levels are usu ally normal or elevated. Fibrinogen levels may be sig nificantly elevated in chronic DIC because fibrinogen may behave as an acute phase reactant in many disor ders associated with chronic DIC, including cancer, autoimmune disorders, and chronic inflammatory dis eases. For similar reasons, Factor VIII and Factor V levels may be normal or elevated in patients with chronic DIC. Like platelets and fibrinogen, increased turnover and decreased survival of Factor VIII:C and Factor V may be seen in patients with chronic DIC. The prothrombin time is usually within normal limits or supernormal in the patient with chronic DIC for reasons previously discussed. Likewise, the APTT is commonly within normal limits or short (super normal).
Red cell fragments, or schistocytes, are present in almost all patients with chronic DIC but are only present in 50% of patients with acute DIC. This is most likely because of the nature of the underlying disease processes giving rise to chronic DIC, such as cancer and related disorders. FDP are almost always elevated in patients with chronic DIC and are quite useful for aiding in a diagnosis. The elevation of these fragments accounts for much of the pathophysiologic findings and low-grade hemorrhage seen in patients with chronic DIC because of the platelet dysfunction that they induce. Soluble fibrin monomer is also com monly detected in patients with chronic DIC and, like the FDP titer, can be quite helpful and is a relatively specific finding. Often, there is also elevated fibrinopeptide A, β-thromboglobulin, platelet factor 4, and Bβ 15-42 related peptides in patients with chronic DIC. Their diagnostic efficacy remains to be deter mined but looks promising. The use of these assays in monitoring efficacy of therapy also remains to be determined; however, they may prove quite helpful. Circulating plasmin associated with hypoplasminogenemia is also a common finding in patients with chronic DIC. In the appropriate clinical setting, the noting of elevated FDP, a positive protamine sulfate test, elevated fibrinopeptide A, elevated Bβ 15-42 pep tides, and hypoplasminogenemia is strongly suggestive of chronic DIC. Table 21 reveals average laboratory values, using commonly available laboratory modalities, in a series of 48 patients with acute DIC. 322 Both average values for pretreatment and post-treatment are given and post-treatment values were derived 4 to 6 hours after therapy that was thought to stop or significantly blunt the intravascular clotting process. It will be noted that the prothrombin time and APTT are borderline pro longed. It is also noted that in the vast majority of pa tients these two tests are corrected to well within nor mal limits after the delivery of effective therapy. The average platelet count was 64,600/mm 3 at the time of making the diagnosis and 204,000/mm 3 after effec- tive therapy. The average fibrinogen level was 129 mg/dl before therapy and 221 mg/dl after therapy. Also of significance is the noting of AT III levels before and after therapy; this will be discussed in more detail subsequently. In this particular series of patients the average biologic AT III level was 58% at the time of making a diagnosis and well within nor mal range 4 to 6 hours after therapy, which was thought to cause cessation or significant blunting of the intravascular clotting process. Laboratory testing and the interpretation of the laboratory results with respect to aiding in a diagnosis and monitoring of therapy in patients with acute DIC remain highly con fusing and, in fact, controversial because very few patient series have actually been published. The reli ability of laboratory testing in patients with acute DIC is depicted in Table 22 . 322 The percentage of abnor mal values pretreatment and the percentage of those remaining abnormal after treatment are depicted for each test in this Table. It will be noticed that in this series of patients, FDP were elevated in 100% of patients at the time of making a diagnosis but remained elevated in 25% of patients after effective therapy. Thus, FDP determinations are of significant diagnostic value but are of only limited value with respect to monitoring efficacy of therapy. The AT III level was noted to be decreased in 97% of patients at the time of making a diagnosis and was only decreased in 16% of patients after therapy, which was thought to be successful at stopping the intravascular clotting process. Thus, the AT III level appears to be quite useful for both aiding in a diagnosis and providing information regarding cessation of the intravascular clotting process.
It can be concluded that the most reliable com monly used laboratory tests for aiding in a diagnosis of DIC and for monitoring efficacy of therapy in acute DIC are the D-dimer assay, the FDP titer, the AT III level, the platelet count, the presence of solu ble fibrin monomer and elevated fibrinopeptide A; these are followed by the thrombin time, fibrinogen level, prothrombin time, APTT, and reptilase time, all of which appear to be generally unreliable. It should be noted in this series of patients that the APTT was only prolonged in 63% of patients at the time of ren dering a diagnosis of acute DIC, thus emphasizing that the APTT is not at all a reliable test for aiding in a diagnosis of DIC or for monitoring of therapy. Table 23 summarizes average pretreatment and post-treatment values for commonly available labora tory modalities in a group of patients with chronic DIC. 2, 76, 321, 322 It will be noted that the prothrombin time and APTT are even less reliable as diagnostic aids in chronic DIC. The fibrinogen level and plate let count are also less useful than in acute DIC. In chronic DIC the average fibrinogen level was 231 mg/dl at the time of making a diagnosis and 330 mg/dl after therapy. The average platelet count was 190,000/mm 3 at the time of making a diagnosis and increased to 254,000/mm 3 after therapy. The AT III level is also less reliable in diagnosing chronic DIC; however, it appears to be almost as useful for moni toring efficacy of therapy as it is in acute DIC. Ta ble 24 depicts the percentage of patients demonstrat ing an abnormal laboratory test at the time of mak ing a diagnosis (pretherapy) and the percentage of those tests remaining abnormal after it was clinically deemed that the intravascular clotting process had been successfully stopped. It will be noticed that the FDP titer was elevated in all patients; however, the titer remained elevated in 50% of patients after ther apy. Likewise, soluble fibrin monomers were present in 80% of patients with chronic DIC but remained circulating in 20% of patients after successful therapy The prothrombin time appears to be more useful in chronic DIC than in acute DIC. The AT III level is of less diagnostic value, being only decreased in 70% of patients with chronic DIC; how ever, after therapy it remained depressed in only 10%, suggesting it to be a useful monitoring modality after therapy. The platelet count, fibrinogen level, APTT, and thrombin time do not appear to be of useful diag nostic significance in chronic DIC. Thus, the reliabil ity of commonly available laboratory tests for aiding in a diagnosis and monitoring therapy in chronic DIC are the FDP product titer, the presence of soluble fi brin monomer, the prothrombin time, and the AT III determination. 2, 76, 238, 239, 322, 323 The reptilase time, platelet count, fibrinogen level, APTT, and thrombin time are of little diagnostic reliability in chronic DIC. Table 25 depicts the probability of pretreatment and post-treatment coagulation abnormalities in all forms of DIC. It appears that the noting of elevated FDP, a depressed AT III level in conjunction with thrombocytopenia, and a positive protamine sulfate test or ethanol gelation test appear to be the most reli able laboratory indices for aiding in and confirming a diagnosis of DIC and for helping to determine the success of therapy. 2, 238, 239, [321] [322] [323] Likewise, other tra ditional tests including the prothrombin time, throm bin time, fibrinogen level, reptilase time, and APTT are less reliable as diagnostic or therapeutic indices. The D-dimer assay and the fibrinopeptide A assay are the most reliable newer tests available. Table 26 com pares older and newer modalities that may be useful in diagnosing and monitoring therapy in DIC. 2, 76, 232 Most newer methods are totally automated or at least automatable and may aid greatly in rendering labora tory data with respect to diagnosis as well as provid ing methods to monitor efficacy of therapy in DIC patients. Molecular marker profiling for DIC has now become available and is fully automatable. 324 " 326 These molecular markers are not only useful for diag nosing DIC, but are also useful for providing a differ ential diagnosis of DIC versus primary fibrinolysis or DIC versus TTP. The differential diagnosis of DIC versus TTP by molecular marker profiling is depicted in Table 27 . The differential diagnosis of DIC versus primary fibrinolysis by automated molecular marker profiling is summarized in Table 28 . In uncommon instances of an extremely difficult differential between 
TREATMENT OF DISSEMINATED INTRAVASCULAR COAGULATION
Acute Disseminated Intravascular Coagulation
The treatment of acute and chronic DIC remains confusing to many and, indeed, controversial. Con comitant with this controversy and confusion is the general feeling that therapy is fruitless and most patients succumb to the disease process. However, most published comments about therapy are based on fiction rather than fact and emotion rather than clin ical judgment. 76 The reasons for this are because very few objective series of patients with DIC, with respect to therapy given, morbidity, mortality, and survival, have been published. Many argue vehe mently against the use of heparin in acute or chronic DIC despite the amazing lack of published case reports or series in the literature regarding the adverse effects of heparin in DIC. [327] [328] [329] Likewise, many argue strongly in favor of the use of heparin in DIC; how ever, there is, likewise, a surprising lack of published reports demonstrating positive effects of heparin in patients with DIC. [330] [331] [332] It is my experience that if logical aggressive and sequential therapy is undertaken in the patient with DIC, morbidity and mortality are not as dismal as suspected. 2, 76, 238, 239, 322 Clinicians and investigators should develop judgment regarding ther apy based on experience and published series of pa tients and documentation, rather than opinion and myth. It is hoped that the future will offer more guide lines than are available at the present time with re spect to successes and failures with various forms of potential therapy.
My approach to therapy in acute DIC is somewhat vigorous and is summarized in Table 29 . Although this approach is rather aggressive, it has been associ ated with a high survival rate (76%) and low mor bidity in patients with classic acute DIC. 2, 76, 238, 239, 322 The most important therapeutic modality to be deliv ered to a patient with acute DIC is that of an aggres sive but reasonable therapeutic approach to remove or treat the triggering disease process that is thought to be responsible for DIC. 76, 238, 239, 322, 333, 334 In some in stances, this is impossible; however, successful ther apy to remove or blunt the triggering event may, in some instances stop or at least significantly blunt the intravascular clotting process. If, however, there are no attempts to treat the triggering event and trigger ing pathophysiologic process, subsequent attempts at anticoagulant therapy, including heparin, will rarely, if ever, alleviate the disseminated intravascular clot ting process. However, attempts to treat the underly ing disease process do give the patient a reasonable chance of responding to therapy designed to stop the intravascular clotting process. In some instances it is impossible or highly unlikely that the underlying dis ease pathophysiologic event can be alleviated. How ever, in many instances the removal of the triggering pathophysiologic event will stop the disease process and the classic example of this is an obstetric accident. More commonly, however, therapy of the underlying process will at least blunt the process enough so that the patient may respond to anticoagulant therapy; however, in some instances this, too, will stop the in travascular clotting process, and another common sit uation in which this occurs is that of septicemia. The successful treatment of septicemia will blunt the pro cess in many patients, thus giving them the opportu nity to respond to anticoagulant therapy; in some instances of septicemia alleviating the triggering patho physiologic event will actually stop the intravascular clotting process. In cases of obstetric accidents of any type, except amniotic fluid embolism, anticoagulant therapy, especially heparin, is rarely required. Simply evacuating the uterus, or in rare instances hysterec tomy, will usually rapidly stop the intravascular clot ting process. 335, 336 Although it is often difficult to convince the obstetrician or gynecologist to take a hemorrhaging hypofibrinogenemic patient to the oper ating room, the results are rewarding when this ap proach is pursued. The results are usually immediate and dramatic. In septicemia, specific antibiotic ther apy, alleviation of shock, volume replacement, the potential use of steroids, and other specific therapy to maintain hemodynamics will often cause significant blunting of the intravascular clotting process and on some occasions may actually stop the DIC process. Each case must, of course, be evaluated on its own merits, depending on the clinical situation and what the clinician feels to be the significant dominant trig gering event. However, the key point is that attempts to treat the triggering event are the most important therapeutic modality that may be delivered to the patient with DIC.
The majority of patients, except those with DIC secondary to obstetric accidents or massive liver fail ure, will subsequently require anticoagulant therapy of some form. The use of subcutaneous low-dose hep arin appears to be highly effective in my experience and has been my choice of anticoagulant therapy for the last 9 years. 2, 76, 238, 239, 322 Anticoagulant therapy is indicated if the patient continues to bleed or clot sig nificantly for approximately 4 hours after the initia tion of therapy to stop or blunt the triggering patho physiologic event. This time period is somewhat empirical and depends on the sites and severity of bleeding. When the patient continues to bleed in this situation, the patient is given subcutaneous calcium heparin at 80 U/kg every 4 to 6 hours as the clinical situation, site and severity of bleeding and thrombo sis, and patient size dictate. It has been noted that low-dose subcutaneous heparin appears to be as effec tive or possibly more effective than larger doses of in travenous heparin in DIC. 2, 76, 229, 238, 239, 337, 338 With this approach, one often notes cessation of AT III consumption, lowering of FDP, and increases in fi brinogen levels and slow or rapid correction of other abnormal laboratory modalities of acute DIC in 3 to 4 hours, followed shortly thereafter by blunting or cessation of clinically significant hemorrhage and thrombosis. The use of subcutaneous low-dose hepa rin rather than intravenous heparin appears reason able for several reasons: (1) If the patient fails to respond, larger doses of heparin can always be admin istered if deemed appropriate; (2) in contrast to what has been feared with larger intravenous doses of hep arin, low-dose subcutaneous heparin therapy is asso ciated with minimal chances of increasing the patient's risk of hemorrhage; and (3) most importantly, the use of low-dose subcutaneous heparin has been as effica cious as large-dose heparin therapy and is associated with a high percentage of patient survival when used in conjunction with other therapeutic modalities. 76 In light of current understanding of the heparin-AT IIIserine protease-thrombin-fibrinogen axis low-dose sub cutaneous heparin, from a theoretical standpoint as well as in published reports, is thought to be equal to or more effective than larger intravenous doses of USP heparin. 229, 337, 338 Other anticoagulant modalities that are available, depending on the clinicians experi ence, are intravenous heparin, the use of combination antiplatelet agents, or the use of AT III concentrates. Those clinicians using intravenous heparin therapy for acute DIC most commonly deliver between 20,000 and 30,000 U/24 hours by constant infusion, and this also may be associated with significant blunting or cessation of the intravascular clotting process. Com bination antiplatelet agents are far less commonly effective in acute DIC, but on occasion may be called for as the specific clinical situation dictates and will be discussed under "Chronic Disseminated Intravascular Coagulation." Acute DIC has been successfully treated with in vestigational AT III concentrates in small groups of patients by several investigators and preliminary expe-rience would suggest these to be quite effective for acute DIC. 2, 254, [339] [340] [341] From a theoretical standpoint, AT III concentrates should be highly effective in treat ing acute DIC and it is hoped that this therapeutic fraction may become available for such use in the near future and that the near future will provide for large-scale clinical trials using this investigational modality to treat this potentially catastrophic disease. With respect to heparin, it is my opinion that subcu taneous heparin, or heparin in any dose, is contraindicated in patients with acute DIC and central nervous system insults of any type, patients with acute DIC associated with fulminant liver failure, and in most instances of obstetric accidents. Approximately 75% of patients will respond to the two previously outlined sequential therapeutic steps. However, if patients con tinue to bleed after initiating reasonable attempts to treat the triggering pathophysiologic mechanism thought to be responsible for DIC and after initiating anticoagulant therapy, the most likely cause of con tinued bleeding is component depletion. In this instance, the exact components missing and clinically thought to be contributing to hemorrhage should be defined as precisely as possible. The delivery of cer tain components is associated with attendant hazards in patients with ongoing DIC and as a general guide line only concentrates and components that are void of fibrinogen should be delivered to a patient with ongoing DIC, ongoing DIC being manifested by con tinued severe depression of the AT III level. If, how ever, the AT III level, or other specific monitoring modality that the clinician chooses to use, is returning to normal and associated with a potential response, it can be assumed that the intravascular clotting process has been controlled, and in this instance any compo nent or concentrate deemed necessary can safely be given. In general, the only components that are gen erally safe in patients with an active uncontrolled DIC process are washed packed red cells, platelet concen trates, AT III concentrates, and nonclotting protein containing volume expanders, such as plasma protein fraction, albumin, and hydroxyethyl starch.
If a patient continues to bleed after successful an ticoagulant therapy and cessation of the DIC process, as manifested by correcting AT III levels, then any component deemed depleted to the point of contrib uting with a high degree of probability to continued hemorrhage is safe to give to the patient. However, it should be emphasized that components containing clotting factors or fibrinogen are, in general, not safe in patients with ongoing DIC, and the use of fresh frozen plasma and fresh whole blood may be associ ated with enhanced hemorrhage and thrombosis in a patient with active DIC to whom these components are unwisely delivered. 2, 238, 239, 342 Not only has this been seen clinically but would be expected from a the oretical standpoint when understanding the patho physiologic mechanism of DIC. If whole blood, fresh frozen plasma, or cryoprecipitate is given to a patient with ongoing DIC, it is to be expected that plasmin will readily biodegrade most, if not all, of the coag ulation factors supplied. This event in itself may not be particularly harmful but is certainly not helpful. Of more significance is that these components contain fi brinogen and are associated with a great potential for creation of even higher levels of FDP, which will fur ther impair hemostasis by interference with fibrin monomer polymerization, further impair already com promised platelet function, and will lead to enhanced microvascular deposition and subsequent thrombocy topenia. Thus, a reasonable approach is to assess the patient after anticoagulant therapy and continued bleeding; if the AT III level, or other selected moni toring modality, has returned to normal or near nor mal, any component deemed significantly depleted and likely to be contributing to continued hemorrhage is reasonable to use. Alternatively, if the patient con tinues to bleed after anticoagulant therapy has been delivered and the AT III level and other modalities used to monitor the patient remain abnormal, it is highly likely in this situation that the intravascular clotting process has not been controlled and contin ues. In this instance the component should be restricted to packed red cells, platelets, volume expanders, and, if available, AT III. By adhering to the three sequen tial aggressive steps just given, greater than 95% of patients will stop hemorrhaging if they are, in fact, going to survive.
The potentially disastrous consequences of using fibrinogen-containing components, in this case plas ma, in a patient with acute ongoing DIC are summa rized in Figure 10 . Although the clotting factors ini tially improved, hemorrhage became worse and the patient exsanguinated. In those rare instances in which bleeding continues after the aforementioned three sequential steps are initiated, the fourth step in the therapy of acute DIC is to consider inhibition of the fibrinolytic system. This step is rarely needed and, in fact, is needed in approximately 3% of patients only. In some rare instances, even though the intra vascular coagulation process has been alleviated, the patient may continue to bleed because, for unexplained reasons, secondary fibrinolysis has continued with the concomitant biodegradation of the usual plasma pro tein targets of plasmin. In this rare instance, and it must be emphasized that this is necessary in less than 3 to 5% of all patients with acute DIC, antifibrinolytic therapy may be indicated. However, it should be emphasized that antifibrinolytic therapy should never be delivered to patients with ongoing DIC because such patients desperately need the fibrinolytic system to keep the microcirculation as clear of microthrombi as possible. 76 Thus, antifibrinolytic therapy should never be delivered unless the first three sequential steps already delineated have been resorted to and it has been well documented from the laboratory and clinical standpoint that the intravascular coagulation process has been terminated by noting correction of biologic AT III levels or other modalities used by the clinician to monitor the event. In addition, antifibri nolytic therapy should never be used unless not only is the cessation of DIC documented, but also the pres ence of significant amounts of plasmin is documented in the laboratory. In those rare instances in which antifibrinolytic therapy is indicated, -aminocaproic acid is given as an initial 5 to 10 gm slow intravenous push followed by 2 to 4 gm/hour for 24 hours or until bleeding ceases. This agent should be used with great caution because it may cause ventricular arrhythmias, severe hypotension, and severe hypokalemia. 343 " 345 In addi tion, it should be realized that if -aminocaproic acid, or any fibrinolytic inhibitor, is used in a patient with ongoing DIC, it may cause enhanced precipitation of fibrin in the microcirculation and macrocirculation and lead to often fatal disseminated thrombosis. 346 It will be noted that in the vast majority of patients depicted, the biologic AT III levels are significantly depressed at the time of making a diagnosis. The exceptions noted in Table 30 are patients with dissemi nated malignancy. Thus, in a patient with acute or chronic DIC and normal or high AT III levels, dis seminated underlying malignancy should be seriously considered and searched for. 54, 76 However, in almost all patients receiving successful therapy there is an associated rapid return to normal or near-normal bio logic AT III levels. Even in those instances when the AT III levels are normal or elevated in association with cancer, the delivery of effective therapy is asso ciated with significant further increases in the AT III level. When the AT III level increases to normal or near-normal levels after the delivery of therapy, it can be assumed with reasonable certainty that the intra vascular coagulation process has undergone cessation or significant blunting. More clinical experience may demonstrate that a drastic decrease of previously ele vated fibrinopeptide A, β-thromboglobulin, or plate let factor 4 levels may be of equal efficacy in assess ing response to therapeutic manipulation in patients with DIC. Table 31 depicts a patient with acute DIC treated with miniheparin. 2, 239 The pretherapy and post-ther apy laboratory values are depicted; within 4 hours there was general correction of laboratory modalities and this was associated with cessation of clinical hem orrhage. Table 32 depicts a patient treated with an investigational AT III concentrate and in this instance the patient not only stopped bleeding and thrombos ing but also survived the DIC process with minimal morbidity. 339
Chronic Disseminated Intravascular Coagulation
Therapy of chronic DIC is approached much differently than that for acute DIC and is summarized in Table 33 . The majority of patients with chronic DIC do not have life-threatening hemorrhage but rather have bothersome hemorrhages, which are often associated with diffuse superficial or deep vein throm bosis and thromboembolism. 231, 347 As with acute DIC, the most important therapeutic modality for a patient with chronic DIC is therapy for the underly ing disease process; in many instances this will cause cessation of the intravascular clotting process and alleviation of hemorrhage and thrombosis. If treat ment for the triggering disease process thought re sponsible for the intravascular coagulation process does not stop the event, at least it will often signifi cantly blunt the process to a degree where bothersome bleeding or thrombosis may cease to be a clinical problem. If this first step is vigorously attempted and hemorrhage or thrombosis or thromboembolism con tinues, then anticoagulant therapy is indicated. How ever, since patients with chronic DIC usually do not have life-threatening hemorrhage, anticoagulant ther apy need not be vigorous in many instances. In fact, vigorous anticoagulant therapy may be contraindicated, in selected instances of cancer, especially those with intracranial metastases. 2, 76, 348, 349 Combination antiplatelet therapy is often successful in stopping a chronic DIC process provided that attempts to treat the triggering pathophysiologic events have also been instituted. A combination of two antiplatelet agents with independent mechanisms of action are often needed. A combination of acetylsalicylic acid, 600 mg orally twice daily to be taken in conjunction with 30 ml of liquid antacid plus dipyridamole, 50 mg orally four times daily, will stop a chronic intravascular co agulation process within 24 to 30 hours, as demon strated by generalized correction of laboratory param eters and the cessation of bleeding or thrombosis, or both. Alternatively, the use of sulfinpyrazone, 200 mg orally three times daily, to be taken in conjunction with 30 ml of liquid antacid plus dipyridamole, 50 mg orally four times daily, may be substituted. 350, 351 Both acetylsalicylic acid and sulfinpyrazone are cyclooxygenase inhibitors leading to a decreased synthesis of thromboxane A 2 ; it is often without avail to use both of these agents in combination, since they have the same mechanism of action. 352 Dipyridamole, how ever, is an inhibitor of phosphodiesterase, leading to increased concentrations of intraplatelet cyclic aden osine monophosphate, 111 and therefore the ideal com bination appears to be acetylsalicylic acid plus dipyr idamole or sulfinpyrazone plus dipyridamole.
Miniheparin, or intravenous heparin is rarely in dicated in patients with chronic DIC; however, lowdose subcutaneous heparin therapy should be consid ered in patients with chronic DIC who appear to be evolving into a more subacute or acute DIC process or who are developing active thrombotic or throm boembolic problems. Replacement therapy is rarely, if ever, indicated in the patient with chronic DIC un-less the patient demonstrates component depletion from other triggering mechanisms, such as the patient with chronic DIC and cancer who also demonstrates thrombocytopenia because of therapy, bone marrow replacement, hypersplenism, or other mechanisms. Inhibition of the fibrinolytic system with -aminocaproic acid is also rarely, if ever, indicated in patients with chronic DIC.
THERAPY OF DISSEMINATED INTRAVASCULAR COAGULATION IN THE PATIENT WITH CANCER
Successful therapy of DIC in the patient with cancer represents a major clinical challenge and is summarized in Table 34 . Effective therapy is mul tiphasic and must be approached in a sequential and logical manner if the process is to be controlled. The first and most important modality to be given is to treat the cancer itself, since this is providing the trig ger or triggers for the intravascular coagulation pro cess. Therapy may be surgical, radiotherapeutic, or chemotherapeutic, as the clinical situation warrants. Treatment of the specific tumor is often associated with cessation or significant improvement in DIC and until attempts at antineoplastic therapy are instituted, subsequent therapy of bleedings or thrombosis is of ten unsuccessful. 2 ' 53 ' 54 ' 239 ' 348 A classic example of re sponse to antineoplastics is seen in the patient with prostatic carcinoma. 353 ' 354 These patients will often show a marked improvement of their hemorrhagic or thrombotic or thromboembolic problems with the institution of diethylstilbesterol therapy or cytotoxic chemotherapy, as clinically indicated; this phenome non may be noted in other tumors as well when anti neoplastic therapy is started. In addition, the use of antiplatelet agents, especially in the form of aspirin plus dipyridamole, as previously outlined, has been associated with correction of altered laboratory tests suggestive of DIC, including normalization of fibrin ogen and platelet survival in patients with cancer and chronic DIC. However, patients with cancer are also notoriously resistant to anticoagulant therapy with respect to stopping minor to moderate bleedings and thrombotic episodes as well as major thrombotic and thromboembolic episodes, all of which are commonly due to a chronic DIC-type process. 2, 53, 54, 348 Table 35 depicts a series of 48 patients to exem plify the incidence of hemorrhages or clinical throm bosis in acute and chronic DIC. 2, 322 This particular series of patients was chosen because the laboratory testing was done by one person and thought to be rea sonably uniform. In patients with acute DIC slightly more than 50% had clinical or laboratory evidence of microvascular and macrovascular thrombosis and all patients had clinical hemorrhages. In those ten pa tients with chronic DIC, eight had clinical or labora tory evidence of thrombosis and all patients had hem orrhages. In this same group survival in patients with chronic DIC was 100% with respect to the DIC pro cess. In addition, patients with acute DIC in this series treated with aggressive therapy as previously outlined demonstrated an overall survival of 76%. Thus, the syndrome of DIC need not be universally associated with a high mortality rate, as has previously been gen erally believed.
SUMMARY
Current concepts of the cause, pathophysiologic mechanisms, diagnosis, and management of acute and chronic DIC have been discussed. Considerable atten tion has been devoted to interrelationships that have remained confusing. Only by clearly understanding these pathophysiologic interrelationships can the cli- This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. nician and laboratorian appreciate the divergent and wide clinical spectrum of often confusing clinical and laboratory findings in patients with DIC. Many of the therapeutic decisions to be made in these patients remain controversial and will remain so until more series of patients are published with respect to specific therapeutic modalities and survival patterns. Many syndromes that remain organ specific share common pathophysiologic properties with DIC but are identi fied as an independent disease entity, such as HUS, adult shock lung syndrome, eclampsia, and many other isolated organ-specific disorders. Many of these similar disorders, some systemic and some organ spe cific or multiorgan specific, are listed in Table 36 .
